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Tumor-nerve interactions including tumor invasion of intra- and extra-pancreatic nerves and pain 
have been extensively documented in pancreatic malignancies. However, little is known about 
the relationship between tumor development and neuroplastic changes in the pancreas. Studies of 
human tissue demonstrate increased neurotrophic factor expression in pancreatic ductal 
adenocarcinoma (PDAC), and neurotrophic factors are known to enhance nerve sprouting and 
sensitization in peripheral afferents. Furthermore, animal studies show that chronic pancreatic 
inflammation produces hypertrophy and hypersensitivity of pancreatic afferents and that sensory 
fibers may themselves drive inflammation via neurogenic mechanisms. These observations led 
us to hypothesize that PDAC-related pain is due to changes in sensory afferent gene expression, 
driven by tumor-derived neurotrophic factors, and that sensitized afferents accelerate the 
transition from precancerous lesions to cancer via neurogenic inflammation.  Using a genetically 
engineered mouse model of PDAC we found that although disease time course varied, pancreatic 
cancer typically developed by 16 weeks of age, however pancreatic neurotrophic factor mRNA 
expression was up-regulated and pancreatic innervation increased dramatically prior to this time 
point.  These changes correlated with pain-related decreases in exploratory activity and increased 
expression of nociception-related genes in sensory ganglia.  Cells of pancreatic origin could also 
be found invading the celiac or sensory ganglia.  These results demonstrate that the nervous 
system participates in all stages of PDAC, including those that precede appearance of cancer. 
Neuroplastic Changes in a Mouse Model of Pancreatic Ductal Adenocarcinoma 
Rachelle Eve Stopczynski, PhD 
University of Pittsburgh, 2013
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1.0  INTRODUCTION 
1.1 PANCREATIC CANCER 
1.1.1 Incidence, mortality, and epidemiology 
In the United States, pancreatic cancer is the tenth most common cancer diagnosis in men and 
the ninth most common cancer diagnosis in women1.  It is estimated that 45,220 new cases of 
pancreatic cancer will be diagnosed in 2013 and approximately 38,460 patients are expected to 
die of the disease1.  This makes pancreatic cancer the fourth leading cause of cancer death in 
both men and women, accounting for 7% of all cancer deaths in the United States1.  
Approximately 95% of pancreatic neoplasms are exocrine tumors, which includes all tumors 
related to ductal cells, acinar cells, and their stem cells, while 5% of malignancies arise from the 
endocrine pancreas1.  Pancreatic ductal adenocarcinoma (PDAC) is the most common type of 
pancreatic cancer, representing greater than 90% of exocrine tumors and 85% of all pancreatic 
neoplasms.  In contrast, other exocrine tumors such as acinar carcinoma and pancreatic 
endocrine neoplasms make up just 1-2% of pancreatic malignancies2.  Most pancreatic cancers, 
up to 85%, are localized to the periampullary region of the pancreas including the head, neck and 
uncinate process, with the remainder in the body and tail3,4.      
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The lifetime risk of developing pancreatic cancer is 1.5% in both men and women1.  
Pancreatic cancer is approximately 30% more common in men than women overall and at every 
age over 35 years1.  Increased age is a significant risk factor, with the likelihood of developing 
pancreatic cancer in the next ten years four times higher at age 70 than at age 50, and a median 
age of 71 at diagnosis1.  Other risk factors include race and ethnicity (highest incidents rates are 
in African Americans, lowest in Asian Americans)1,5, low socioeconomic status5, tobacco use6, 
obesity7,8, heavy alcohol use9, diabetes10–12, and chronic pancreatitis13–17.   
Family history, particularly in a first-degree relative, and certain genetic factors are also 
associated with increased risk of developing pancreatic cancer (reviewed in18–23).  Approximately 
10% of PDAC cases are thought to be familial22.  Germline mutations in the breast cancer 2, 
early onset (BRCA2) gene, which are associated with hereditary breast and ovarian cancer 
syndrome, account for the highest proportion of known causes of inherited pancreatic cancer24–26, 
and both breast cancer 1, early onset (BRCA1) and BRCA2 mutations are associated with 
increased risk of pancreatic cancer24,25,27–29.  Germline mutations in the gene linked to familial 
atypical multiple mole-melanoma (FAMMM) syndrome, cyclin-dependent kinase inhibitor 2A 
(CDKN2A), also confer increased risk of developing pancreatic cancer29–31.  Other hereditary 
cancer syndromes such as Peutz-Jeghers syndrome (linked to mutations in serine/threonine 
kinase 11; STK11) and Hereditary Non-polyposis Colorectal Cancer syndrome (HNPCC; linked 
to mutations in MutL homolog 1, colon cancer, nonpolyposis type 2; MLH1 and mutS homolog 
2, colon cancer, nonpolyposis type 1;MSH2) are associated with increased risk of pancreatic 
cancer32–34.  Germline mutations in the ataxia-telangiectasia mutated gene (ATM) have also been 
described in families with familial pancreatic cancer.35 Patients with hereditary pancreatitis, 
which is associated with mutations in protease, serine, 1 (PRSS1)36, also have a significantly 
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increased risk of developing PDAC13–15,36,37.  In these patients, the lifetime risk of developing 
pancreatic cancer is 40-55%, which is a 70 times greater risk than the general population13.   
1.1.2 Prognosis and treatment 
Despite increased research focus, the estimated 5-year survival rate for PDAC remains just 6%, 
with median survival time after diagnosis ranging from 24.1 months for patients diagnosed with 
stage IA disease to 4.5 months for patients with stage IV disease38. Several factors are thought to 
be responsible for the high fatality rate associated with this disease including poor early 
detection, early metastatic spread and lymph node involvement, and local invasion of 
retroperitoneal structures such as the superior mesenteric artery and the celiac plexus1,39–43.   
For patients with PDAC, treatment is largely based on the resectability of the tumor at 
presentation.  Complete surgical resection is currently the only potentially curative treatment for 
patients with pancreatic cancer. Unfortunately, 80-85% of patients have stage III or IV disease at 
the time of diagnosis and are not candidates for surgical resection1,38.  Criteria for un-
resectability of PDAC tumors include superior mesenteric artery or celiac artery encasement, 
unreconstructable superior mesenteric vein or portal vein occlusion, aortic invasion or 
encasement, metastases to lymph nodes beyond the field of resection, and distant metastases44.   
Although surgical resection has the potential to be curative, five-year survival is 
approximately 20-25% in patients with negative margins following surgical resection and 
approximately 10% in patients with positive margins1,4,45.  Predictors of poor survival following 
surgery include positive resection margins, poor tumor differentiation, tumor size, lymph node 
involvement, the presence of perineural invasion, and high preoperative or persistently elevated 
carbohydrate antigen 19-9 (CA19-9)4,38,40,45–57.  Adjuvant treatment with chemotherapy or 
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chemoradiotherapy has been shown to improve survival outcome after surgery48,58,59.  
Additionally, the value of neoadjuvent chemotherapy or chemoradiotherapy to identify patients 
most likely to benefit from surgical resection, to increase the likelihood of achieving negative 
margins following tumor resection, and to potentially treat early micrometastatic disease is 
currently being studied59,60.  
In patients with metastatic disease, response to mono-treatment with 5-fluorouracil (5-
FU) or gemcitabine is generally poor, however combination therapy with 5-FU, leucovorin, 
irinotecan, and oxaliplatin (FOLFIRINOX) has been shown to prolong life in patients who are 
able to tolerate the increased toxicity.  Symptom management and palliative care are important 
components of PDAC treatment and often focus on relieving PDAC-related pain, depression, 
gastric outlet obstruction, delayed gastric emptying, obstructive jaundice, and pancreatic 
insufficiency (reviewed in1,61,62).  Both monotherapy with gemcitabine as well as FOLFIRINOX 
have been shown to significantly improve quality of life for patients with metastatic PDAC63,64.         
1.1.3 Symptoms  
In patients with PDAC the most common presenting symptoms, regardless of disease stage, are 
pain, jaundice, and weight loss1,3,42,62,65 (reviewed in66–68).  In the case of tumors in the body or 
tail of the pancreas, symptoms may not be apparent until very late in disease progression, when 
metastatic disease is often present67.  In one study of 185 patients diagnosed with exocrine 
pancreatic cancer, asthenia and anorexia were present in >80% of patients whereas nausea, 
diarrhea, and vomiting were present in 33-51% of patients3.  This study also found that jaundice 
was the most frequent sign at the time of diagnosis in 55% of patients and hepatomegaly was the 
next most common in 39%3. PDAC pain is generally epigastric or abdominal, radiating to the 
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sides or back, although severe back pain in the absence of abdominal pain is reported by some 
PDAC patients68. For a more detailed discussion of pain related to PDAC, see 1.3 CANCER 
PAIN.  Jaundice associated with PDAC is significantly more common in patients with tumors in 
the head of the pancreas, particularly at early stages of the disease68.  Additionally, painless 
jaundice is more frequent at early stages of disease whereas jaundice with abdominal or back 
pain, is more common at advanced stages68.  
Other symptoms are less common at the time of disease presentation but may develop as 
the disease progresses (reviewed in39).  This includes duodenal obstruction leading to gastric 
outlet obstruction62, delayed gastric emptying associated with nausea and vomiting69, abdominal 
ascites39, depression70–72, and cachexia73.  Metastatic disease in PDAC commonly affects the 
liver, peritoneum, and lungs (reviewed in39,74).  
1.1.4 Precursor lesions and PDAC histopathology     
Several types of noninvasive epithelial neoplasms have been shown to give rise to PDAC, 
including intraductal papillary mucinous neoplasms (IPMNs), mucinous cystic neoplasms 
(MCNs), and pancreatic intraepithelial neoplasia (PanIN).  Of these, PanIN lesions are the most 
common and their progression to PDAC has been extensively documented75,76 (reviewed in74).  
PanIN typically occur in smaller pancreatic ducts and can be found in the pancreas of healthy 
patients, particularly with advanced age74,75,77,78.  PanIN are also found in the pancreas of patients 
who are at high risk for developing PDAC77.  A classification system has been developed to 
grade PanIN lesions based on graded stages of dysplasia, increasing architectural 
disorganization, and appearance of nuclear abnormalities76.  Squamous metaplasia typically 
proceeds PanIN lesions and describes a process in which cuboidal ductal epithelium is replaced 
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by mature stratified squamous or transitional epithelium76.  PanIN-1A and -1B are epithelial 
lesions with tall columnar cells and basally located nuclei and supranuclear mucin76.  PanIN-2 is 
a mucinous epithelial lesion that may be flat or papillary and contains nuclear abnormalities.  
PanIN-3 is classified as epithelial lesions that are typically papillary or micropapillary, 
cribriforming, clusters of epithelial cells in the duct lumen, luminal necrosis, loss of nuclear 
polarity, and nuclear abnormalities76. High grade PanIN transition to PDAC is evidenced by the 
presence of invasion beyond the basement membrane76.  The progression from PanIN to PDAC 
is associated with an accumulation of genetic mutations (discussed in 1.1.5 Molecular 
pathogenesis of PDAC).   
Less commonly, larger precursor lesions give rise to PDAC.  IPMNs are also mucinous 
epithelial lesions, however these involve the main pancreatic duct or major branches and are 
large enough to be grossly or radiologically visable76.  MCNs are also larger than PanIN and are 
cystic lesions characterized by the presence of ovarian-type stroma around the cyst and lack of 
connection to the duct system76.  Similar to PanIN, IPMNs and MCNs are accompanied by 
accumulation of genetic mutations74,79,80. 
One study of precancerous lesions in the pancreas of patients at high risk of developing a 
pancreatic malignancy, found multifocal IPMN and PanIN lesions ranging from grade 1A-377.  
In the majority of cases examined, regions of lobular parenchymal atrophy, characterized by loss 
of acinar cells, aggregation of islets, fibrosis, and fatty replacement of the pancreas, were 
associated with PanINs or IPMNs77.  A different study found a significant association between 
PanINs and fibrosis in the pancreas of individuals older than 60 years of age78.  Fibrotic changes 
associated with PanINs and IPMNs are thought to be due to small duct obstruction caused by the 
neoplasia77,78.       
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Grossly, exocrine tumors of the pancreas are solid, scirrhous masses with poorly defined 
borders.  PDAC tumors range from well- to moderately- to poorly- differentiated based on the 
extent to which the tumor cells morphologically resemble normal cells of the tissue. 
Differentiation has been shown to influence prognosis with well- or moderately- differentiated 
tumors associated with better prognosis, regardless of tumor stage81.  PDAC tumors are 
characterized by a dense desmoplastic stroma, perineural tumor invasion (discussed in detail in 
1.1.6 Tumor microenvironment, inflammation, and metastatic spread and 1.2.1 Perineural 
invasion), and limited vascularization.     
1.1.5 Molecular pathogenesis of PDAC 
While controversy remains as to what the cellular origins of PDAC are, pancreatic tumorigenesis 
involves progression from normal ducts to cancer precursor lesions to carcinoma driven by a 
combination of genetic mutations that are both inherited and acquired over time. Over 90% 
percent of pancreatic cancers have mutations in the v-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog (KRAS) gene, a human homolog of a gene isolated from the Kirsten rat 
sarcoma virus82–85.  KRAS, a GTP-binding protein, is a member of the RAS protein family and 
mediates a variety of cellular functions including proliferation, differentiation, and survival 
(reviewed in74). Activating mutations in KRAS cause the protein product to have decreased 
enzymatic activity and to be insensitive to GTPase activating proteins86.  However, though 
enzymatic activity is inactivated, KRAS is actively signaling as long as it binds GTP, which in 
the case of the activating mutations means that KRAS is constitutively active86.  Most 
commonly, activating mutations are point mutations in codon 12, resulting in substitution of 
glycine with valine, arginine, or most often, aspartate (reviewed in74). Interestingly, KRAS 
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mutations are also found in precursor lesions known to progress to PDAC.  Mutations in KRAS 
have been shown to be in IPMNs87, MCNs80, and PanIN88.  Furthermore, the prevalence of KRAS 
mutations found in precursor lesions increases, as the degree of dysplasia increases80,87.  The 
early appearance of KRAS mutations in the pancreas suggests that oncogenic KRAS is involved in 
the formation of cancer precursor lesions as well as the development and maintenance of PDAC.  
This hypothesis is further supported by studies of transgenic mouse models of PDAC in which 
mutations in KRAS drive the formation of PanIN and eventually PDAC89,90 (see 1.4.2 
Genetically engineered mouse models of PDAC).        
Other important genetic mutations in PDAC are inactivating mutations in the tumor 
suppressor genes tumor protein p53 (TP53), CDKN2A, and Smad family member 4 (SMAD4), 
which occur in more than 50% of pancreatic cancers83,85,91–95.  The CDKN2A gene encodes for 
the protein p16INK4A, a G1 cyclin-dependent kinase (CDK), and is located on chromosome 
9p91,92.  Somatic inactivating mutations in CDKN2A occur in approximately 95% of pancreatic 
tumors91,92 and germline mutations in the gene are one of the causes of FAMMM syndrome.  
Inactivation of CDKN2A is thought to occur early88 and cooperates in the development of PDAC 
with activated KRAS.  The CDKN2A locus also encodes an overlapping tumor suppressor 
protein, p14ARF, that inhibits TP53 degradation (reviewed in74). Mutations in the other two tumor 
suppressor genes generally occur in more advanced stages of neoplasia, after the acquisition of 
KRAS and CDKN2A mutations (reviewed in74).  The TP53 gene, one of the most commonly 
mutated genes in human cancers, is involved in many cellular functions including regulation of 
proliferation and apoptosis93.  Inactivation of TP53 occurs in 75-80% of pancreatic tumors, often 
via intragenic mutation coupled with loss of the second allele83,93. Inactivation of the SMAD4 
gene occurs83,94 in approximately 60% of pancreatic tumors, and loss of heterozygosity is found 
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in 90% of tumors (reviewed in74). The protein product of SMAD4 functions in the intracellular 
signaling pathway of transforming growth factor beta (TGFβ) receptor activation96 and mutations 
in genes coding for other components the TGFβ signaling pathway have also been reported in 
pancreatic tumors97.  
How each of these mutations contributes to the development of neoplasia and subsequent 
transition to PDAC is not entirely understood.  However, downstream effects could include 
alterations in a wide variety of signaling pathways including TGFβ, mitogen-activated 
kinase/extracellular signal-regulated kinase (MAPK/ERK), phosphoinositide-3-kinase (PI3K), 
nuclear factor κB (NFκB), epidermal growth factor (EGF), insulin-like growth factor (IGF), 
hepatocyte growth factor (HGF), fibroblast growth factor (FGF), and vascular endothelial growth 
factor (VEGF) (reviewed in74) Developmental signaling pathways, such as Hedgehog, Notch, 
and Wnt, likely also play a role in PDAC pathogenesis (reviewed in74).         
1.1.6 Tumor microenvironment, inflammation, and metastatic spread 
The tumor microenvironment also plays a critical role in PDAC pathogenesis (reviewed in98–101). 
PanIN formation is typically accompanied by focal fibrosis and inflammation, suggesting that 
both may plan an important role early in disease pathogenesis (reviewed in102). Inflammatory 
changes in the pancreas cause tissue damage and the release of cytokines, growth factors, and 
reactive oxygen species, which induce cell proliferation and DNA damage associated with tissue 
repair that could drive the accumulation of genetic changes related to malignant transformation 
and tumor development (reviewed in103,104). The strong relationship between chronic pancreatitis 
and the development of PDAC13–17,37, as well as the presence of KRAS105 mutations and PanIN 
lesions75,106 in chronic pancreatitis support this hypothesis.  Furthermore, studies using 
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transgenic mouse models of PDAC have shown that acute pancreatitis accelerates the 
development of cancer in mice expressing activating Kras mutations107–111 (discussed in 1.4.2 
Genetically engineered mouse models of PDAC).      
Similar processes of pancreatic stellate cell (PSC) recruitment and extracellular matrix 
(ECM) remodeling associated with stroma formation have been described in both PDAC and 
chronic pancreatitis, suggesting that inflammation in the pancreas may be an initiating event in 
PDAC-related stroma formation as well.  A variety of cytokines and growth factors associated 
with inflammation in the pancreas have been shown to activate PSCs, and activated PSCs are 
thought to be responsible for secreting ECM components that form the desmoplastic stroma112,113 
(reviewed in98,99).  The dense, desmoplastic stroma contains a cellular component that includes 
invading tumor cells, PSCs, fibroblasts, and inflammatory cells, and an extracellular component 
that includes glycoproteins, collagen, and proteases (reviewed in98,100).  Growth factors and 
signaling molecules such as Hedgehog, HGF, FGF, and TGFβ create a positive feedback loop 
between tumor cells and PSCs driving tumor proliferation and migration, ongoing inflammation, 
and the expansion of the stroma (reviewed in98–100,114).  One study demonstrated that stroma 
activity correlates with poorer prognosis115 and the dense stroma surrounding the tumor as well 
as its avascular nature are thought to contribute to chemoresistance in PDAC.  Blocking these 
components has been shown to increase tumor response to treatment with gemcitabine in a 
mouse model of PDAC116.  
Inflammation has also been shown to promote epithelial-mesenchymal transition 
(EMT)117, which is thought to be an early step in metastatic spread.  EMT allows tumor cells to 
dissociate from the epithelial layer via the down-regulation of molecules involved in cell-cell 
adhesion and acquisition of migratory capabilities (reviewed in99).  Interestingly, in a mouse 
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model of PDAC, EMT and dissemination of pancreatic cells into the bloodstream was shown to 
occur at precancerous stages of tumor development, before PDAC was histologically evident117.  
This suggests that not only might inflammation in the pancreas influence the progression from 
PanIN to PDAC, but it may also drive the early dissemination of pancreatic cells related to 
metastases.    
1.2 TUMOR-NERVE INTERACTIONS 
1.2.1 Perineural invasion 
Tumor-nerve interactions have been documented in a variety of cancers including PDAC, 
prostate cancer, skin cancer of the head and neck cancer, and oral cancers (reviewed in118–127). 
Metastases along nerves and perineural invasion (PNI) are commonly associated with these 
malignancies and previous studies have shown that intrapancreatic perineural invasion is present 
in up to 100% of PDAC cases (reviewed in118,128,129).  Perinerual invasion is typically defined as 
the presence of malignant cells in the perineural space, but can involve tumor cell invasion of the 
epineurium, perineurium, or endoneurium.   
1.2.1.1 Perineural invasion and disease prognosis 
Intra- and extra-pancreatic perineural invasion correlate with worse disease prognosis.  Extra-
pancreatic PNI tumor invasion represents an important component of locally invasive disease 
and is a significant predictor of positive tumor margins following tumor resection.  PNI has also 
been shown to correlate with post-operative recurrence and decreased survival time52–57,130–133. 
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Tumor spread along pancreatic nerves could also serve as a mode of dissemination of distant 
metastases.  One study found continuity between cancer cells invading peripheral nerves and 
cancer cells invading lymph nodes134, and perineural invasion has been shown to be  
significantly correlated with lymph node invasion52,135.  This suggests that PNI may contribute to 
lymph node involvement in the disease, another significant predictor of poor outcome in 
PDAC52–54,133,135.   
Lymph node involvement and retroperitoneal tumor invasion, potentially via nerves, 
directly affect resectability criteria in patients and perineural invasion of extra-pancreatic nerve 
plexuses has also been proposed as a potential reservoir of tumor cells left behind following 
tumor resection that could contribute to local recurrence of the disease129.  Given that surgical 
tumor resection represents the only potentially curative intervention for patients with PDAC, PNI 
may be a significant barrier to disease treatment and improved survival.  
Perineural tumor invasion not only provides a mode for local and distant spread of 
disease, it is also thought to play a role in the development of PDAC-related pain122,136 
(discussed in 1.3.2 Mechanisms of pancreatic pain).  PNI damages peripheral afferents and 
exposes the nerves to an intense inflammatory milieu containing a variety of cytokines and 
growth factors that can induce changes in sensory afferent phenotype, resulting in pain. 
1.2.1.2 Proposed mechanisms of PNI in PDAC 
The mechanisms underlying perineural tumor invasion in PDAC are not currently known, but 
likely involve reciprocal signaling between tumor cells and pancreatic afferents.  The list of 
potential signaling molecules includes neurotrophic factors (discussed in 1.2.2.1 Neurotrophic 
factors in PDAC), axon guidance proteins, cytokines, neurotransmitters, and adhesion 
molecules (reviewed in119).     
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A recent study using genomic sequencing and pathway-based mutation analysis identified 
mutations and copy-number variants in genes related to axon guidance in resected tumors from a 
cohort of patients with stage I and stage II PDAC85.  Specifically, alterations in the proteins 
involved in axon guidance during development, such as slit homolog 2 (Drosophila) (SLIT2) 
and/or roundabout, axon guidance receptor, homolog 1/2 (Drosophila) (ROBO1/2) were 
identified, and decreased ROBO2 expression was associated with poorer survival, as was 
increased expression of ROBO3, an inhibitor of ROBO2 signaling85.  Significant amplification of 
class 3 semaphorins (SEMA3A and SEMA3E), another group of proteins involved in growth cone 
axon guidance, was also observed and increased SEMA3A expression was associated with poor 
survival85  These data suggest that signaling between tumor cells and pancreatic nerves may 
invoke mechanisms similar to those involved in axon guidance during development. 
Furthermore, it points to a similarity between neural progenitor cells present during normal 
development and PDAC tumor cells.   
Activated sensory afferents are known to release a variety of molecules including 
glutamate, calcitonin-related polypeptide α (CGRP), and substance P (SP).  Release of these 
molecules in the pancreas has been implicated in neurogenic inflammation associated with 
pancreatitis (reviewed in137), and they may also play a significant role in perineural invasion.  
Both SP and its receptor, tachykinin receptor 1 (NK1R), are expressed in pancreatic cancer cell 
lines and SP induces cancer cell proliferation, invasion, and expression of metalloproteinase-2 
(MMP-2) in vitro138.  SP/NK1R signaling provides a link between perineural invasion and 
neurogenic inflammation in the pancreas, which suggests that a common mechanism, such as 
peripheral afferent sensitization, could underlie both phenomena.   
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Cytokines and chemokines from a variety of sources such as tumor cells, infiltrating 
immune cells, and PSCs have also been linked to perineural neural invasion in PDAC.  
Chemokine (C-X3-C motif) receptor 1 (CX3CR1) is expressed by PDAC cell lines and in PDAC 
tissue, whereas its ligand chemokine (C-X3-C motif) ligand 1 (CX3CL1), or fractalkine, is 
expressed by neurons and peripheral nerve fibers.  CX3CR1 signaling induces tumor cell 
migration in vitro, and promotes peripheral nerve infiltration by transplanted tumors in vivo139.   
Increased expression of L1 cell adhesion molecule (L1-CAM) in PDAC tissue is 
significantly correlated with perineural invasion and poorer prognosis, implicating adhesion 
molecule signaling in the mutual tropism between tumor cells and pancreatic nerves140 as well.  
Other studies have shown that a type 1 transmembrane mucin, MUC1, is overexpressed in 
pancreatic cancer and enhances adhesion between pancreatic cancer cells and Schwann cells in 
vitro via binding of myelin-associated glycoprotein (MAG), which is expressed on 
oligodendrocytes and Schwann cells and binds myelin to neurons141.  Given the variety of 
molecules associated with tumor cell migration and invasion in vitro and perineural invasion in 
PDAC tissue, it is likely that a pattern of gene expression, rather than a single factor, is necessary 
for the initiation and progression of perineural tumor invasion in PDAC.     
1.2.2 Neurotrophic factors  
The neurotrophins and glial cell line-derived neurotrophic factor (GDNF) family ligands regulate 
survival, development, and plasticity of the peripheral nervous system (reviewed in142,143). 
Members of the neurotrophins include nerve growth factor (NGF) and brain-derived 
neurotrophic factor (BDNF) and members of the GDNF family ligands include GDNF, artemin 
(ARTN), and neurturin (NRTN).  NGF and BDNF signal through tropomyosin-related kinase 
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receptor type 1 (TRKA) and type 2 (TRKB), respectively, which then dimerize and activate 
intracellular signaling cascades  (reviewed in144).  GDNF family ligands each bind a preferred, 
high affinity glycoslyphosphatidylinositol-linked receptor- α (GFRα), and the ligand-receptor 
complex then binds the extracellular domain of the receptor tyrosine kinase (RET), triggering 
downstream intracellular signaling cascades (reviewed in142).  GDNF preferentially binds 
GFRα1, NRTN preferentially binds GFRα2, and ARTN preferentially binds GFRα3.  Our lab 
and others have shown that these neurotrophic factors also drive postnatal sprouting and 
sensitization of primary sensory afferents145–154  The tumor microenvironment contains a variety 
of inflammatory mediators and neurotrophic factors in the pancreas which can act on exposed 
pancreatic sensory afferents, stimulating nerve hypertrophy, promoting perineural invasion, and 
enhancing sensory neuron excitability and pain (discussed in 1.3.2 Mechanisms of pancreatic 
pain). 
1.2.2.1 Neurotrophic factors in PDAC 
Studies of resected tumor tissue have shown that a variety of neurotrophic factors and 
neurotrophic factor receptors are expressed in PDAC.  GDNF, GFRα1, NGF, TRKA, ARTN, 
and GFRα3 are increased in human PDAC tissue compared to normal control pancreas140,155–162 
and NGF and ARTN are significantly correlated with the degree of nerve hypertrophy155,156.  
Similar observations of nerve hypertrophy and remodeling associated with increased 
neurotrophic factor expression have been described in studies of chronic pancreatitis163–167, 
suggesting that these changes are also associated with pancreatic inflammation and fibrosis and 
thus, likely begin at pre-malignant time points in PDAC development. Increased nerve 
hypertrophy and neural density in resected tissue from patients with PDAC and chronic 
pancreatitis are correlated with increased expression of growth associated protein 43 (GAP-43), 
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increased perineural invasion, and severity of patient-reported abdominal pain136.  The effects of 
tumor-derived neurotrophic factors on afferents have also been demonstrated in vitro.   
Significant increases in neurite density were observed in isolated myenteric plexuses exposed to 
extracts from human PDAC156,168 compared to normal medium, and this effect was blocked when 
NGF or ARTN was depleted from the tumor extract156.  One group suggests that PDAC-related 
hyperglycemia could induce the release of neurotrophic factors such as NGF from pancreatic 
tumor cells as well as directly damage pancreatic afferents via glucose toxicity169–171.  
PDAC cell lines have been shown to express a variety of growth factor receptors 
including TRKA, TRKB, GFRα1, GFRα2, and GFRα3, suggesting that neurotrophic factors in 
the tumor microenvironment can also influence tumor cells119.  Increased NGF, TRKA, TRKB, 
and GDNF expression in human PDAC tissue correlates with the degree of PNI157,158,160,162,172 
and in vitro studies show that ARTN, GDNF, and NGF promote invasive behavior of human 
PDAC cell lines155,161,173–178.  One proposed mechanism for neurotrophic factor-induced tumor 
cell migration and invasion is increased expression of MMPs such as MMP-2177.  Another in 
vitro study implicated GDNF-mediated activation of the ERK and PI3K pathways in pancreatic 
tumor cell migration and invasion178.  Thus, neurotrophic factor signaling in the pancreas could 
contribute to disease progression directly by enhancing proliferation, migration, and invasion in 
tumor cells or indirectly via sensitization of pancreatic afferents.  Increased NGF, TRKA, and 
GDNF expression in PDAC is also correlated with the severity of patient reported 
pain119,157,159,162, suggesting that intrapancreatic neurotrophic factor expression in PDAC 
sensitizes pancreatic sensory afferents, resulting in pain.   
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1.3 CANCER PAIN 
Many cancer patients will experience moderate to severe pain at some point during disease 
development and progression, with pain frequency and intensity increasing at later stages of 
disease (reviewed in179–181).  Pain may be present at the time of cancer diagnosis or develop later 
as a direct result or side effect of cancer treatments and procedures or due advanced disease, 
metastases, or paraneoplastic syndromes (reviewed in180,181).  Both tumor- and treatment-related 
pain syndromes can be chronic or acute in nature, complicating the balance between symptom 
management and disease treatment.  Cancer-related pain has a profoundly negative effect on 
patient quality of life71,72, and a significant number of patients report inadequate pain control.  A 
number of different issues contribute to undermanaged cancer pain including incomplete 
knowledge of the underlying molecular mechanisms (reviewed in181).  A better understanding of 
the pathophysiology of cancer pain will provide better, more efficacious treatment options with 
few side effects, thereby improving quality of life and survival in cancer patients.   
1.3.1 Pancreatic pain 
PDAC is associated with significant morbidity, particularly pain, which is associated with 
increased incidence of depression71,72, decreased quality of life71,72,  and worse prognosis68,136.  
Similarly, pain is one of the most common and debilitating symptoms of patients with chronic 
pancreatitis (reviewed in182).  Pancreatic pain can be caused by a variety of intra- and extra-
pancreatic processes such as increased ductal pressure due to obstruction, ischemia, fibrosis, 
sensitized pancreatic afferents, duodenal stenosis, or common bile duct stenosis (reviewed in183). 
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Pancreatic pain has proven difficult to treat effectively.  Use of nonsteriodal anti-
inflammatory drugs and narcotic analgesics to relieve pain are generally the first line treatment, 
however they demonstrate limited efficacy and are associated with numerous adverse effects as 
well as the development of opioid dependence184.  Celiac plexus blockade (CPB), either 
temporary or permanent, is one of the current options for treating patients with pancreatic pain 
(reviewed in182,185–187).  Typically, an injection of a local anesthetic such as bupivacain and a 
corticosteroid is made into the celiac plexus for temporary CPB, and injection of alcohol or 
phenol into the celiac plexus produces permanent CPB.  Unfortunately, the response rate 
following either temporary or permanent CPB is variable for patients with pancreatic pain and 
even for patients that experience a reduction in pain, the post-interventional pain-free interval is 
limited (reviewed in185–188).  Thus far no randomized control trials have directly compared the 
efficacy of opioid analgesics and CPB in pancreatic cancer patients. Current evidence suggests 
the two treatments may be comparable, though CPB is associated with a lower risk of side 
effects and may be effective in patients in who are refractory to narcotic analgesics (reviewed 
in182,185–188).  Similarly, denervation of the pancreas via bilateral transection of splanchnic nerves 
provides some patients with chronic pancreatitis short-term pain relief, though resection of the 
head of the pancreas remains the most efficacious treatment (reviewed in186,187).  One potential 
reason for the poor sustained response to pancreatic denervation is that patients with pancreatic 
pain demonstrate evidence of central sensitization and impaired descending inhibitory pain 
modulation189, suggesting that either interventions targeting peripheral afferent denervation 
should occur earlier in disease progression to prevent central sensitization, or that treatments 
occurring later require centrally-mediated interventions.    
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1.3.2 Mechanisms of pancreatic pain 
Numerous molecules and processes likely contribute to the development of pancreatic 
neuropathy and pain including nerve damage and neurogenesis, immune cell infiltration, 
chemokines and cytokines, neurotrophic factors, and glial activation (reviewed in179,180,190–192). 
Inflammatory cytokines, such as interleukin 1, β (IL-1β), interleukin 6 (IL-6), and tumor necrosis 
factor α (TNFα), released by a variety of immune cells and pancreatic stromal cells have been 
shown to act directly on peripheral sensory afferents and induce hypersensitivity in a variety of 
neuropathic, inflammatory pain models (reviewed in193,194).  Increased cytokine expression and 
astrocyte activation in the spinal cord have also been associated with chronic pancreatitis pain in 
a trinitrobenzene sulfonic acid (TNBS) induced rodent chronic pancreatitis model195,196 and 
several studies using rodent models of bone and facial cancer pain have also implicated altered 
central glial activation and up-regulated cytokine signaling in the pathophysiology of cancer 
pain197–203 (reviewed in179).  
Additionally, chemokines such as fractalkine have also been implicated in pancreatic 
pain, as strong neuro-immunoreactivity for fractalkine and its receptor, CX3CR1, correlates with 
more severe pain in patients with chronic pancreatitis204,205.  Increased fractalkine in human 
chronic pancreatitis is also associated with enhanced pancreatic infiltration of lymphocytes and 
macrophages and pancreatic neuritis205.  Pancreatic neuritis is frequently observed in pancreatitis 
as well as PDAC tissue and increased neuritis is associated with a higher patient-reported pain 
score 136,166,185,206, increased neural density136, and nerve hypertrophy136.  Cytotoxic T-
lymphocytes, macrophages, and mast cells are most commonly found infiltrating intra-pancreatic 
nerves and increased perineural mast cells is associated with the presence of pain206.      
 20 
Along with nerve injury due to pancreatic neuritis and the effects of inflammatory 
mediators on pancreatic afferent hypersensitivity, activation of two non-specific cation channels, 
transient receptor potential cation channel vanilloid 1 (TPRV1) and transient receptor potential 
cation channel ankyrin 1 (TRPA1) is associated with pancreatic afferent activation and pain 
(reviewed in207).  TRPV1 responds to a variety of stimuli including capsaicin, noxious heat 
temperatures (> 42°C), and acid, while TRPA1 responds to stimuli including noxious cold 
(<17°C) temperatures, mustard oil, cinnamon oil, and bradykinin (reviewed in208,209).  In mouse 
models of acute and chronic caerulein-induced pancreatitis, significantly more cultured 
pancreatic afferents respond to capsaicin or mustard oil application210,211 and agonist-evoked 
intracellular calcium transients are potentiated211.   Other rodent studies have also demonstrated 
TRPV1 and TRPA1 activation and enhanced pancreatic afferent excitability associated with 
pancreatitis212–214.  Furthermore, exposure of cultured dorsal root ganglion (DRG) neurons to 
neurotrophic factors potentiates TRPV1-induced calcium transients215, and blockade of NGF 
attenuates pancreatic hyperalgesia and decreases TRPV1 activation and expression in pancreatic 
sensory neurons214.  Thus, inflammation- or cancer-derived neurotrophic factors in the pancreas 
likely drive pancreatic afferent sensitization via TRPV1 and TRPA1 activation. 
1.3.3 Pancreatic pain and neurogenic inflammation 
Studies of pancreatitis pain suggest that stimulation of sensory afferents and subsequent TRPV1 
and TRPA1 activation also drives neurogenic inflammation in the pancreas210,211,216–219 (reviewed 
in137,207).  Neurogenic inflammation is characterized by vasodilation, edema, and thermal and 
mechanical hyperalgesia and is thought to be due release of CGRP and SP in the pancreas 
(reviewed in137,207).  Furthermore, caerulein-induced pancreatic inflammation and edema is 
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attenuated by treatment with TRPV1 and/or TRPA1 antagonists210,211,220 or treatment with a 
NK1R antagonist220.  Sensory denervation of the pancreas, via neonatal capsaicin injection, prior 
to dibutyltin dichloride (DBTC) or caerulein induced pancreatitis inhibited pancreatic 
inflammation and attenuated the rate of pancreatic fibrosis and glandular atrophy in rats216,221.  
Ablation of TRPV1-expressing sensory neurons by resiniferatoxin, a neurotoxin and TPRV1 
agonist, similarly ameliorated caerulein induced pancreatitis218. However, genetic deletion of 
TRPV1 in mice does not protect against pancreatitis218 suggesting that another signaling cascade 
leading to sensory afferent sensitization and neuropeptide release exists, such as TRPA1. Taken 
together, these studies of neurogenic inflammation in rodent models of pancreatitis provide 
evidence that peripheral afferents play an important role in pancreatic pain and inflammation.  
Furthermore, additional studies using genetically engineered mouse models of PDAC are 
necessary to determine whether sensitized pancreatic afferents drive pain, inflammation, and 
disease progression in PDAC as well.   
1.4 ANIMAL MODELS  
1.4.1 Animal models of cancer pain 
Previous studies of pancreatic cancer pain in a mouse model of acinar cell carcinoma222, a 
relatively rare pancreatic exocrine malignancy, demonstrated increased density of sensory and 
sympathetic fibers, increased microvascular density, and increased NGF-expressing macrophage 
infiltration in the pancreas at precancerous and early stage disease223. In this model, pain-related 
hunching and vocalizations were not significantly increased as compared to wild type controls 
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until late stages of disease, when large tumors were present.  Pain-related hunching severity in 
cancer mice with advanced stage disease was attenuated by acute administration of morphine 
sulfate223 and administration of the central nervous system-penetrant opioid receptor antagonists, 
naloxone and naltrexone, induced hunching and vocalizations in cancer mice with pre-malignant 
or early stage disease224. These data suggest that endogenous opioid signaling may suppress pain 
at pre-malignant and early stages of cancer development, potentially delaying the detection of an 
underlying pancreatic malignancy.      
Other groups have studied the molecular mechanisms of cancer pain using rodent models 
of metastatic bone, oral, or head and neck cancer.  Bone cancer pain is typically related to 
metastatic spread, therefore rodent models of bone cancer pain typically utilize injection of 
prostate or mammary gland cancer cells into the tibia or femur, producing spontaneous pain-
related behavior and evoked mechanical and thermal hyperalgesia, to recapitulate human disease 
and identify neuroplastic changes associated with tumor-induced pain 201,203,225–230. In one model 
of bone cancer pain in which osteolytic murine sarcoma cells are surgically implanted into the 
femur, blockade of TRK signaling attenuates tumor-induced sprouting of sensory and 
sympathetic nerve fibers, neuroma formation, and pain231.  Early and sustained treatment with 
the selective small molecule TRK inhibitor was necessary to prevent sarcoma-induced neural 
remodeling and pain231.  In a similar model of murine bone pain, early, preventative or late 
treatment with an NGF-sequestering antibody attenuates sensory nerve sprouting, neuroma 
formation and nociceptive behaviors induced by canine prostate carcinoma cells implantation in 
the femur226,232–234.  
Another model of murine cancer pain in which fibrosarcoma cells are implanted in and 
around the calcaneus bone produces hyperalgesia to mechanical stimuli in the ipsilateral paw that 
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is dose-dependently attenuated by morphine administration235, partially blocked by intra-tumor 
injection of a CGRP receptor anatagonist236, and significantly alleviated with systemic 
antagonism of TNFα237,238.  In this model, a subset of C-fibers adjacent to the tumor developed 
spontaneous activity and exhibited decreased heat thresholds within two weeks of tumor growth, 
and these changes in sensory afferent phenotype were accompanied by increased branching of 
epidermal nerve fibers in the skin overlaying the tumor239, supporting the hypothesis that similar 
processes underlie both tumor-induced hyperinnervation and afferent sensitization.   
A chemically induced model of head and neck cancer and injection of oral squamous cell 
carcinoma cells (SCC) or SCC supernatant have been established as models of chronic head and 
neck cancer pain, persistent oral cancer pain, and acute oral cancer pain, respectively240. In these 
models, interaction between protease-activated receptor 2 (PAR2) and serine proteases is critical 
for the development of acute and chronic cancer pain240.  Furthermore, serine protease inhibition 
attenuates persistent cancer pain whereas chronic cancer pain development is prevented in 
PAR2-deficient mice240.  In a similar model of oral cancer pain in which human oral cancer cells 
(HSC-3) are implanted into the plantar surface of the hindpaw or into the floor of the mouth, 
treatment with an anti-NGF antibody decreased nociception and weight loss as well as inhibited 
tumor proliferation241.  Anti-NGF treatment also decreased expression of TRPV1, TRPA1 and 
PAR2 in trigeminal ganglia neurons241. 
1.4.2 Genetically engineered mouse models of PDAC 
The relatively limited improvement in early detection, treatment, and survival in pancreatic 
cancer over the past 50 years led to an increased focus on developing preclinical models of the 
disease, and a variety of xenograft, carcinogen-induced, and genetically engineered models of 
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the disease are currently available (reviewed in74,242–247). Activating KRAS mutations such as 
KRASG12D are found in nearly all human PDAC tumors as well as precancerous PanIN lesions 
(discussed in 1.1.5 Molecular pathogenesis of PDAC). Expression of KrasG12D targeted to 
murine pancreatic cells leads to acinar-to-ductal metaplasia and the formation of PanIN lesions 
in the pancreas of transgenic mice89 (reviewed in242,245).  Furthermore, the importance of 
KrasG12D in PDAC development and progression was recently demonstrated in transgenic mice 
expressing an inducible KrasG12D in which expression of oncogenic KrasG12D leads to formation 
of precursor lesions, whereas inactivation of KrasG12D during cancer progression leads to 
regression of precancerous lesions90.   
Insertion of a LoxP flanked gene silencing “Stop” cassette (LSL) upstream of the Kras 
promoter restricts expression of the endogenous mutated KrasG12D, based on Cre recombinase248 
excision of the silencing cassette.  Specific expression of a conditional LSL-KrasG12D allele249,250 
in pancreatic progenitor cells is achieved by crossing the LSL-KrasG12D knock-in strain with a 
transgenic strain expressing either pancreas duodenum homeobox 1-Cre (Pdx1-Cre) or pancreas 
specific transcription factor 1a-Cre (Ptf1a-p48-Cre)89. Both Pdx1 and Ptf1a-p48 are expressed 
in early pancreatic progenitors cells that give rise to endocrine and exocrine cell lineages251 
(reviewed in246). 
Inactivating mutations in the tumor suppressor genes TP53, p16INK4/CDKN2A, and 
SMAD4, occur in more than 50% of human PDAC tumors (discussed in 1.1.5 Molecular 
pathogenesis of PDAC), and each has been targeted in the development of transgenic mouse 
models of PDAC as well.  Progression from precancerous lesions to invasive and metastatic 
adenocarcinoma was infrequently observed in Ptf1a-p48-Cre; LSL-KrasG12D and Pdx1-Cre; LSL-
KrasG12D mice89,252–254.  However, when expression of the mutated KrasG12D is combined with 
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p16Ink4a/p19Arf, Smad4, or Trp53 inactivation, PanIN lesions rapidly progress to invasive 
adenocarcinoma in transgenic mice252–254.  In these transgenic mouse models, histology, 
pathology, pathophysiology, molecular, and clinical aspects of PDAC closely parallel what is 
observed in human PDAC (reviewed in243).  Interestingly, recent studies have demonstrated that 
pancreatitis also significantly accelerates the progression from PanIN to PDAC in transgenic 
mice expressing LSL-KrasG12D 107–111, which is consistent with the significant association 
between chronic pancreatitis and PDAC development in human disease.      
1.5 DISSERTATION GOALS  
The goal of my dissertation is to test the hypothesis that PDAC-related pain is due to changes in 
sensory afferent gene expression, driven by tumor-derived neurotrophic factors.  These changes 
in growth factor expression and sensory afferent gene expression are further hypothesized to 
sensitize pancreatic afferents and in so doing, drive neurogenic inflammation in the pancreas and 
promote the development and progression of PDAC.  In order to test this hypothesis, and to 
elucidate the temporal dynamics of disease progression, pain development, intra-pancreatic 
innervation, neurotrophic factor expression changes, and changes in sensory afferent gene 
expression, I measured behavioral, gene expression, anatomical, and calcium ion handling 
parameters over time in an established transgenic mouse model of PDAC.   
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1.6 SUMMARY 
In this study, we demonstrate that changes in pain-related behavior are evident in PDAC mice as 
the disease progresses, though there is considerable variability in time course among PDAC 
mice.  We describe neuroplastic changes in the pancreas of PDAC mice that closely parallel the 
neuroplastic changes previously described in human PDAC specimens, and importantly, these 
changes begin prior to the appearance of cancer.  Finally, neuroplastic changes in the pancreas 
are accompanied by up-regulation of genes related to nociception and neurogenic inflammation 
in sensory afferent neurons.     
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2.0  METHODS 
2.1 MOUSE STRAINS  
We established the line of PDAC transgenic mice from breeders generously supplied by the 
laboratory of Dr. Ronald DePinho (MD Anderson Cancer Center, Houston, TX). PDAC mice 
produced on C57BL/6 and FVB backgrounds were backcrossed 4 times with C57BL/6 mice, 
resulting in transgenic mice that are genetically 93.75% identical to the C57BL/6 strain.  PDAC 
mice express a conditional activated (mutant) Kras allele targeted to the endogenous Kras locus 
under Lox-Stop-Lox control (LSL-KrasG12D)249,250, a conditional Trp53 allele with LoxP sites in 
intron 1 and intron 10 of the Trp53 gene (p53Lox)254,255, and Ptf1a-p48-Cre (p48-Cre)89,251, as 
described previously 89,117,254.  Mice with the genotypes LSL-KrasG12D; p53+/+, LSL-KrasG12D; 
p53lox/+, LSL-KrasG12D; p53LoxlLox or any conditional allele alone were used as age- and sex-
matched littermate controls. To better visualize cells of pancreatic origin, PDAC mice were 
crossed with a ROSA-LSL-tdTomato reporter strain (B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J; 
The Jackson Laboratory, Bar Harbor, ME) to produce tPDAC mice in which all cells of 
pancreatic origin express tdTomato, a red fluorescent protein.  Transgenic mice expressing p48-
Cre and ROSA-LSL-tdTomato  but neither LSL-KrasG12D nor p53Lox were used as age- and sex-
matched control tdTomato mice.  
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Transgenic offspring were genotyped at 2 weeks of age using DNA isolated from tail 
skin.  Mice were lightly anesthetized with inhaled isoflurane and a small (5mm) tail snip was 
removed.  Tails were digested in 480μl of lysis buffer (200mΜ NaCl, 100mΜ Tris pH 8.0, 
10mM EDTA, 0.5% SDS) and 20μl of proteinase K (10 mg/ml) overnight at 55°C.  To extract 
the DNA,165μl of 5N NaCl was added and tubes were centrifuged for 5 minutes at 10,000 
revolutions per minute (rpm).  DNA was precipitated in 800μl of 100% ethanol (EtOH), 
centrifuged for 10 minutes at 10,000 rpm to form a pellet, rinsed twice in 75% EtOH, and 
centrifuged for 5 minutes at 10,000 rpm after each rinse.  The DNA pellet was dried for 5 
minutes and reconstituted in 200μl of TE buffer (10mM Tris pH 8.0, 1mM EDTA pH 8.0).  
Polymerase chain reaction (PCR) analysis of 100ng of DNA was done using HotStar Taq DNA 
polymerase (Qiagen, Valencia, CA) using primer set sequences provided by the DePinho 
laboratory (LSL-KrasG12D, p53Lox, and p48-Cre) and The Jackson Laboratory (ROSA-LSL-
tdTomato), listed in Table 1.  Amplified DNA was separated by gel electrophoresis on a 2% 
agarose (GeneMate, BioExpress, Kaysville, UT) gel with ethidium bromide (0.5μg/ml; 
Invitrogen, Life Technologies, Grand Island, NY) in TAE buffer (40mM Tris acetate, 1mM 
EDTA pH 8.0).     
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Table 1. Primer squences for genotyping PDAC and tPDAC transgenic strains 
      
 
 
PDAC and tPDAC mice were analyzed at time points between weaning (post-natal day 
21) through terminal disease, typically 25-30 weeks of age. Tissue was harvested at 3-4 weeks, 
6-8 weeks, 10-12 weeks, and greater than 16 (>16) weeks. Due to the relatively few PDAC and 
tPDAC mice produced in each litter, both male and female mice were used to reach appropriate 
experimental group sizes.   
All animals were housed in the Association for Assessment and Accreditation of 
Laboratory Animal Care-accredited Division of Laboratory Animal Resources at the University 
of Pittsburgh in a 12 hour light/dark cycle with a temperature-controlled environment and ad 
libitum access to water and food.  Animals were cared for and studies were performed in 
accordance with guidelines of the Institutional Animal Care and Use Committee at the 
University of Pittsburgh and the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals.     
Transgene Primers 5’ 3’ 
LSL-KrasG12D 3’-Flank-3’    
LoxP1 
TCCGAATTCAGTGACTACAGATG 
 5’-Kozak-3’  
LoxP1 
CTAGCCACCATGGCTTGAGT 
p53Lox Intron 1  
Forward 
CACAAAAACAGGTTAAACCCAG 
 Intron 1  
Reverse 
AGCACATAGGAGGCAGAGAC 
Ptf1a-p48-Cre Cre 26 CCTGGAAAATGCTTCTGTCCG 
 Cre 36 CAGGGTGTTATAAGCAATCCC 
 Gabra 12 CAATGGTAGGCTCACTCTGGGAGATGATA 
 Gabra 70 AACACACACTGGCAGGACTGGCTAGG 
ROSA-LSL-tdTomato IMR 9020 AAGGGAGCTGCAGTGGAGTA 
 IMR9021 CCGAAAATCTGTGGGAAGTC 
 IMR 9103 GGCATTAAAGCAGCGTATCC 
 IMR 9105 CTGTTCCTGTACGGCATGG 
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2.2 SICKNESS AND HUNCHING ASSESSMENT 
PDAC, tPDAC, and littermate control mice were weighed weekly beginning at postnatal day 28 
to monitor sickness severity.  Animals were additionally monitored for the appearance of tumor 
sequelae such as jaundice, abdominal swelling due to ascites, and decreased locomotion.  
Additionally, PDAC and tPDAC mice were scored weekly based on a hunching/sickness scale 
adapted from the one previously developed by Mantyh and colleagues in a mouse model of 
pancreatic acinar carcinoma 223,224.  Scores were assigned as follows: 0= no rounded-back 
posture and healthy-appearing coat; 1= mild rounded-back posture and healthy-appearing coat; 
2= moderate rounded-back hunched posture and slight piloerection; 3= moderate to severe 
rounded-back hunched posture and moderate piloerection; 4= severe rounded-back hunched 
posture, whole body piloerection, altered gait, and limited locomotion.  Hunching score served as 
a surrogate marker of sickness severity and animals receiving a hunching score 4 were 
euthanized.   
2.3 PANCREAS AND METASTASIS HISTOLOGY AND 
IMMUNOHISTOCHEMISTRY 
2.3.1 Tissue preparation  
Histological analysis and pancreatic innervation was examined in PDAC, tPDAC, and control 
mice at age 3-4 weeks, 6-8 weeks, 10-12 weeks, and >16 weeks.  Animals were euthanized by 
overdose of inhaled isoflurane and transcardially perfused with 4% paraformaldehyde (PFA) in 
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0.1Μ phosphate buffer (PB, pH 7.4).  The pancreas, stomach, and duodenum were dissected out 
en bloc and separate parts of liver and lung were removed if metastases were grossly visible. The 
tissue was post-fixed in 4% PFA for 2 hours at room temperature (RT), cryoprotected in 25% 
sucrose in 0.1Μ PB overnight at 4°C, embedded in Tissue-Tek OCT compound (Sakura Finetek, 
Torrance, CA), sectioned on a cryostat at 30µm, and serially mounted on Superfrost Plus slides 
(Fisher Scientific Company, Pittsburgh, PA).  
2.3.2 Hematoxylin and eosin staining 
Pancreas and metastasis histology was visualized with hematoxylin and eosin staining. Tissue 
sections were dehydrated in serial alcohols as follows: 2x water for 5 minutes, 2x 50% EtOH for 
30 seconds, 2x 75% EtOH for 30 seconds, 2x 95% EtOH for 1 minute, 2x 100% EtOH for 2 
minutes, and 2x Fisherbrand Citrisolv clearing agent (Fisher Scientific Company, Pittsburgh, 
PA) for 5 minutes.  Sections were then rehydrated through the sequence of EtOH in the reverse 
order, dipped in hematoxylin (Thermo Scientific, Pittsburgh, PA) for 10 seconds, rinsed in water, 
dipped quickly 5 times in eosin (Thermo Scientific, Pittsburgh, PA), and rinsed in water.  
Sections were again dehydrated through serial alcohols as described above, coverslipped with 
DPX mounting medium (Electron Microscopy Sciences, Hatfield, PA), and viewed and 
photographed on a LEICA DM 4000B microscope (Leica Microsystems, Wetzlar, Germany) 
using Leica Application Suite (LAS) software (Leica Microsystems, Wetzler, Germany.  
Sections of pancreas from at least four PDAC mice per age group were reviewed and scored by 
Dr. Douglas J. Hartman, Assistant Professor of Pathology, University of Pittsburgh.    
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2.3.3 Immunohistochemistry 
Immunofluorescence was used to visualize nerves in the pancreata and metastatic spread in 
tPDAC and control tdTomato mice.  Tissue sections were washed in 0.1Μ PB, incubated in 
blocking buffer [BB; 5% normal horse serum (Thermo Scientific, Pittsburgh, PA) and 0.25% 
Triton X-100 (Thermo Scientific, Pittsburgh, PA) in 0.1Μ PB] for 30 minutes at RT, incubated 
in primary antibody diluted in BB overnight at RT, and washed with 0.1Μ PB.  Primary 
antibodies used were rabbit anti-protein gene product 9.5 (PGP 9.5; 1:1000, UltraClone Limited, 
Wellow, Isle of Wight, England), rabbit anti-tyrosine hydroxylase (TH; 1:200, Cell Signaling 
Technology, Danvers, MA), and rabbit anti-calcitonin-related peptide α (CGRP; 1:1000, Sigma-
Aldrich, St. Louis, MO). Binding of primary antibodies was visualized with donkey anti-rabbit 
secondary antibody conjugated to Cy2 (1:500, Jackson ImmunoResearch Laboratories, West 
Grove, PA) diluted in in 0.1Μ PB.  Tissue sections were incubated in secondary antibody for 2 
hours at RT, washed in in 0.1Μ PB, dehydrated in Fisherbrand Citrisolv clearing agent, and 
coverslipped with DPX mounting medium.  Sections were photographed using LAS software 
and a LEICA DM 4000B microscope. 
2.4 OPEN-FIELD EXPLORATORY BEHAVIOR  
To assess pain-related behavior throughout tumor development in PDAC mice, open-field 
exploratory behavior was analyzed at time points ranging from 7-31 weeks of age.  As 
previously described 210,211, mice were placed in plexiglass boxes and open-field exploratory 
activity was measured photoelectrically at a 0.75 cm spatial resolution for a period of 15 minutes 
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using TruScan software (Coulbourn Instruments, Whitehall, PA).   The software analyzed 
movements, time spent moving, velocity of movement, distance travelled, and time spent in 
different areas of the behavior arena.  Both horizontal measurements in which the animals were 
moving along the floor of the arena and vertical measurements in which the animals were 
extending or rearing upward were analyzed. Some animals were tested repeatedly, at a frequency 
of approximately two weeks, however no habituation to the test was apparent in PDAC or 
control mice.  The total monitoring period was divided into 3 blocks of 5 minutes and data for 
each behavior measurement were analyzed using a linear mixed effects models with age, 
genotype, and time block treated as fixed effects and each individual animal treated as a random 
effect to account for intra-animal correlation.  Analyses were performed using the R package 
lme4 and p-values for the fixed effects were based on likelihood ratio tests. These statistical 
analyses were performed by Dr. Daniel P. Normolle, Associate Professor of Biostatistics, 
University of Pittsburgh.  Data were also binned based on discreet age ranges corresponding to 
different stages in tumor development (6-8, 10-12, and >16 weeks) and differences between 
cancer and control mice were analyzed using a two-way analysis of variance (ANOVA). Within 
age comparisons between PDAC and control mice were performed using the Bonferroni 
correction (Matlab, MathWorks, Natick, MA).  All statistical analyses performed in Matlab were 
done by Dr. Anoopum S. Gupta, Department of Medicine, UPMC.     
2.4.1 Naloxone treatment 
To determine the effect of endogenous opioid blockade on open-field exploratory behavior in 
PDAC mice, animals were injected with the μ-opioid receptor antagonist, naloxone 
hydrochloride (4 mg/kg in sterile saline, subcutaneously; Sigma, St. Louis, MO) 30 minutes prior 
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to activity monitoring as described above.  PDAC mice and matched controls were 17- 31 weeks 
of age at the time of testing and each PDAC mouse was scored a 1 or 2 on the hunching scale.  
The number of cancer and control mice exhibiting decreased behavior was compared for each 
behavior measurement using Mann Whitney U tests (SPSS Statistics; IBM Corporation, 
Armonk, NY).  A percent change score [(post-naloxone treatment – baseline)/baseline] for each 
behavior measurement was calculated for each mouse.  Average percent change score for PDAC 
and control mice were compared for each beahavior measurement using Mann-Whitney U tests 
(Matlab, Mathworks). 
2.5 CELIAC GANGLION AND DORSAL ROOT GANGLIA  
IMMUNOHISTOCHEMISTRY 
2.5.1 Tissue preparation 
Celiac ganglia from tPDAC and tdTomato control mice >16 weeks of age were analyzed for the 
presence of tdTomato+ cells of pancreatic origin and expression of activating transcription factor 
3 (ATF3), a marker of nerve injury.  Animals were euthanized by overdose of inhaled isoflurane 
and transcardially perfused with 4% PFA.  The celiac ganglion was dissected out, post-fixed for 
1hour at RT, and cryoprotected in 25% sucrose in 0.1Μ PB overnight at 4°C.  In one tPDAC 
mouse, a tdTomato+ tumor metastasis was found encasing the spinal cord at the level of thoracic 
vertebra 9-12 (T9-12).  This section of spinal cord with associated DRG was dissected, post-
fixed, and cryoprotected.  Cryoprotected tissue was embedded in 10% porcine gelatin (~300 
bloom, Sigma-Aldrich, St. Louis, MO) in 0.1Μ PB, fixed for 30 minutes in 4% PFA, and gelatin 
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blocks were cryoprotected in 25% sucrose in 0.1Μ PB overnight at 4°C.  Floating tissue sections 
were cut at 20µm using a sliding microtome.    
2.5.2 Immunohistochemistry 
Immunofluorescence was used to visualize tdTomato+ cells within the celiac ganglion and 
expression of ATF3 in celiac ganglion neurons.  Sections of celiac ganglion were washed in 
0.1Μ PB, incubated in BB for 30 minutes at RT, incubated in primary antibody diluted in BB 
overnight at RT, and washed with 0.1Μ PB.  Primary antibodies used were rabbit anti-PGP 9.5 
(1:1000, UltraClone Limited), rabbit anti-TH (1:200, Cell Signaling Technology), and rabbit 
anti-ATF3 (1:200, Santa Cruz Biotechnology).  Binding of primary antibodies was visualized 
with donkey anti-rabbit secondary antibody conjugated to Cy2 (1:500, Jackson ImmunoResearch 
Laboratories) diluted in in 0.1Μ PB.  Tissue sections were incubated in secondary antibody for 2 
hours at RT, washed in in 0.1Μ PB, and mounted on Superfrost Plus slides in 0.1% porcine 
gelatin in 0.1Μ PB.  Sections were coverslipped with Vectashield mounting media (Vector 
Laboratories, Burlingame, CA) and photographed using LAS software and a LEICA DM 4000B 
microscope.  Sections of spinal cord with attached DRG were processed as described above for 
PGP9.5 and ATF3.         
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2.6 DRG RNA ISOLATION AND QUANTITATIVE REVERSE TRANSCRIPTION-
PCR (qRT-PCR) 
Changes in gene expression in the DRG of PDAC mice at 10-12 and >16 weeks of age were 
assessed using qRT-PCR.  Animals were euthanized by overdose of inhaled isoflurane, 
transcardially perfused with 0.9% saline, and DRG from T9-T12 were removed bilaterally as 
these levels have previously been shown to receive the majority of innervation from the pancreas 
256.  DRG were immediately frozen on dry ice and RNA isolated using RNeasy Mini kits 
(Qiagen, Valencia, CA).  RNA was treated with DNAse (Invitrogen, Life Technologies, Grand 
Island, NY) to remove genomic DNA, and 300ng -1µg was reverse-transcribed using Superscript 
II (Invitrogen, Life Technologies, Grand Island, NY).  SYBR Green-labeled PCR amplification 
using Absolute QPCR SYBR Green ROX mix (Thermo Scientific, Pittsburgh, PA) was 
performed on an Applied Biosystems 7000 real-time thermal cycler controlled by Prism 7000 
SDS software (Applied Biosystems, South San Francisco, CA).  Threshold cycle (Ct) value, the 
cycle number at which SYBR Green fluorescence rises above background, was recorded as a 
measure of initial template concentration.  Relative fold changes in RNA levels were calculated 
using the ∆∆Ct method 257 with glyceraldehyde 3-phosphate dehydrogenase (Gapdh) used as a 
reference standard for normalization.  Significance was determined using Mann-Whitney U-tests 
(SPSS Statistics).  Primers sets for GAPDH, transient receptor potential cation channel vanilloid 
1 (Trpv1), transient receptor potential cation channel ankyrin 1 (Trpa1), sodium voltage-gated 
channel 1.8 (Nav. 1.8), potassium voltage-gated channel 4.3 (Kv 4.3), Cgrp, substance P (SP), and 
Atf3 were designed using ABI software (Molecular Biology Insights, Cascade, CO) or found in 
PrimerBank (Massachusetts General Hospital, Boston, MA) 258 and are listed in Table 2. 
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Table 2.  Murine primer sequences for qRT-PCR 
Gene Forward (5’ 3’) Reverse (5’ 3’) 
Artn GGCCAACCCTAGCTGTTCT TGGGTCCAGGGAAGCTT 
Atf3 TGAGCCACTTTGTGCCAACA TGTGCCCAGGGTTCTTCCT 
Bdnf CACTGGCTGACACTTTTGAGCAC GCTGTGACCCACTCGCTAATACTG 
Cgrp TCAGCATCTTGCTCCTGTACCA CTGGGCTGCTTTCCAAGATT 
Gapdh ATGTGTCCGTCGTGGATCTGA ATGCCTGCTTCACCACCTTCTT 
Gdnf GCACCCCCGATTTTTGC AGCTGCCAGCCCAGAGAATT 
Gfrα1 GTGTGCAGATGCTGTGGACTAG TTCAGTGCTTCACACGCACTTG 
Gfrα2 TGACGGAGGGTGAGGAGTTCT GAGAGGCGGGAGGTCACA 
Gfrα3 CTTGGTGACTACGAGTTGGATGTC AGATTCATTTTCCAGGGTTTGC 
Kv4.3 TGAATCTTTCTGGTACACCATAGT GCTAAAGTTGGAGACTATCACAGG 
Nav1.8 GCCACCCAGTTCATTGCCTTTTC TCCCCAGATTCTCCCAAGACATTC 
Ngf ACACTCTGATCACTGCGTTTTTG CCTTCTGGGACATTGCTATCTGT 
Nrtn TGAGGACGAGGTGTCCTTCCT AGCTCTTGCAGCGTGTGGTA 
SP GCAAAGCACAGTGATGAAGAAGC TGAAAGCAGAACCAGGGGTAGC 
Trka AGAGTGGCCTCCGCTTTGT CGCATTGGAGGACAGATTCA 
Trkb CCGGCTTAAAGTTTGTGGCTTAC GGATCAGGTCAGACAAAGTCAAG 
Trpv1 TTCCTGCAGAAGAGCAAGAAGC CCCATTGTGCAGATTGAGCAT 
Trpa1 GCAGGTGGAACTTCATACCAACT CACTTTGCGTAAGTACCAGAGTGG 
 
2.7 BACK-LABELING OF PANCREATIC AFFERENTS  
To examine changes in pancreatic sensory afferent phenotype in PDAC mice throughout tumor 
development (ages 6-8, 10-12, and >16 weeks), pancreas-specific sensory neurons were back-
labeled with 1,1’-dioctadecyl-3,3,3’3’-tetramethylindocarbocyanine perchlorate (DiI), a 
fluorescent lipophilic indocarbocynanine dye. 
2.7.1 Animal surgery 
All surgical procedures were performed under aseptic conditions and aseptic technique was used 
throughout.  Anesthesia was initiated by inhaled 4% isoflurane and maintained with inhaled 2% 
isoflurane.  As previously described 210,211,256, a laparotomy was performed to expose the 
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pancreas/tumor, and multiple injections of a total volume of 5µl of DiI (2% suspension in sterile 
saline; Invitrogen, Life Technologies, Grand Island, NY) were made.  After the injections, 
abdominal muscles and overlying skin were sutured separately and mice were allowed to recover 
for 8-10 days following the surgery.   
2.8 PRIMARY DRG CELL CULTURE AND CALCIUM IMAGING 
2.8.1 DRG cell culture 
Acute primary DRG cell cultures were prepared for calcium (Ca2+) imaging as previously 
described 147,148,215,259–261.  Animals were euthanized by an overdose of inhaled isoflurane and 
transcardially perfused with 4°C calcium-/magnesium- free Hank’s balanced salt solution 
(HBSS; Gibco, Life Technologies, Grand Island, NY).  Bilateral thoracic DRG 9-12 were rapidly 
dissected into ice cold HBSS and then incubated in 60U papain (Worthington, Lakewood, NJ) in 
a solution of cysteine (1mg/3ml HBSS) and saturated NaHCO3 for 10 minutes at 37°C.  The 
solution was removed and replaced with 3ml HBSS with 12mg collagenase Type II 
(Worthington, Lakewood, NJ) and 14mg dispase Type II (Roche Diagnostics, Indianapolis, IN) 
for 20 minutes at 37°C.  The collagenase/dispase solution was removed and replaced with 1ml 
Advanced DMEM/F12 media (Gibco, Life Technologies, Grand Island, NY) plus 10% fetal 
bovine serum (FBS; Gibco, Life Technologies, Grand Island, NY) and 1% 
Penicillin/Streptomycin (Pen/Strep; Gibco, Life Technologies, Grand Island, NY).  Cells were 
spun at 1500g for 30 seconds, the pellet was resuspended in 550µl of fresh media and 
resuspended cells plated on laminin/poly-lysine coated coverslips (BD Biosciences, Bedford, 
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MA).  The coverslips were incubated for 2 hours at 37°C then fed with Advanced DMEM/F12 
media.  Calcium imaging was performed 2.5-6 hours after plating.  
2.8.2 Calcium imaging  
Cells were loaded with Ca2+ indicator by incubation for 30 minutes in normal bath solution 
(NBS; HBSS, 1.4mM CaCl2, and 0.9mM MgSO4) containing 5mg/ml bovine serum albumin 
(BSA) and 2µΜ of the acetoxymethyl ester of fura-2 (Invitrogen, Life Technologies, Grand 
Island, NY) at 37°C.  Coverslips were placed on an Olympus upright microscope stage with NBS 
at 30°C flowing at 5ml/minute.  Perfusion rate was controlled with a gravity flow system 
(Warner VC65; Warner Instruments, Hamden, CT) and perfusate temperature maintained with a 
heated stage and in-line heating system (Warner PH1, SHM-6, TC344b; Warner Instruments, 
Hamden, CT).  Drugs were delivered with a rapid-switching local perfusion system.   
Firmly attached DiI+-neurons were identified and selected as regions of interest using 
HCImage software (Hamamatsu Corporation, Sewickley, PA).  Fields were first tested with a 
brief application of 50mM KCl (High K+) and Ca2+ transients measured to identify responsive 
neurons.  Ca2+ transients were measured as the ratio of absorbance at 340nm to absorbance at 
380nm (ΔF340/380; Lambda DG4, Sutter Instrument, Novato, CA; Retiga 1300, QImaging, 
Burnaby, BC, Canada) with ΔF340/380 > 0.20 considered a response (easily distinguished from 
optical noise of ΔF340/380 < 0.02).  Cells that were not responsive to High K+ were not included in 
further analyses.  Ca2+ transients were measured in response to application of either 1µΜ 
capsaicin (Sigma-Aldrich, St. Louis, MO) diluted in NBS from a stock solution of 10mM 
capsaicin in 1-methyl-2-pyrrolidinone or 100µΜ mustard oil (Sigma-Aldrich, St. Louis, MO) 
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diluted in NBS from 100mM mustard oil dissolved in 1-methyl-2-pyrrolidinone.  These doses 
were chosen based on previous studies done in our laboratory showing responses of ΔF340/380 > 
0.10 from the maximal number of responding cells 147,148,210,215,260,261.     
In the protocol for each coverslip, cells were first tested with a 7 second application of 
High K+ and allowed to recover to baseline (typically 5 minutes).  Then, cells were tested for 
responses to either a 9-10 second capsaicin (1µΜ) application or 18-20 second mustard oil 
application and allowed to return to baseline (typically 10 minutes).  The number of capsaicin or 
mustard oil responsive cells was calculated as a percentage of healthy (High K+- responsive) 
cells and compared between PDAC and control afferents at each time point (6-8 weeks, 10-12 
weeks, >16 weeks) using Chi square tests (SPSS Statistics).  Ca2+ peak percent response to High 
K+ [(Peak ΔF340/380 – Baseline ΔF340/380)/ Baseline ΔF340/380] for all responsive cells (ΔF340/380 > 
0.20) was compared between PDAC and control pancreatic afferents at each time point using a 
two-way ANOVA. Within age comparisons between PDAC and control mice were performed 
using the Bonferroni correction (Matlab, MathWorks).                      
2.9 PANCREAS RNA ISOLATION AND QRT-PCR  
Changes in growth factor and growth factor receptor gene expression in the pancreas of PDAC 
mice at 3-4, 6-8, 10-12, and >16 weeks of age were assessed using quantitative real time RT-
PCR. The pancreas/tumor from animals deeply anesthetized with 0.1-0.2cc ketamine/xylazine 
was removed, immediately homogenized in 2mL Trizol reagent (Invitrogen, Life Technologies, 
Grand Island, NY), and frozen on dry ice. RNA was extracted using 400µl chloroform, 
precipitated in 800µl isopropanol overnight at -80°C, washed twice with 75% EtOH, and 
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resuspended in 100-200µl RNase-free water (Invitrogen, Life Technologies, Grand Island, NY). 
RNA samples were further purified using RNeasy columns (Qiagen, Valencia, CA). RNA 
samples were treated with DNAse and 1µg was reverse-transcribed using Superscript II.  SYBR 
Green-labeled PCR amplification using Absolute QPCR SYBR Green ROX mix was done as 
described in 2.6 DRG RNA ISOLATION AND QUANTITATIVE REVERSE 
TRANSCRIPTION-PCR (qRT-PCR). Primer sets for nerve growth factor (Ngf), artemin 
(Artn), glial cell line- derived neurotrophic factor (Gdnf), brain-derived neurotrophic factor 
(Bdnf), neurturin (Nrtn), tropomyosin-related kinase, type 1 and type 2 (Trka and Trkb), and 
glycosylphosphatidylinositol-linked receptor α1, α2, and α3 (Gfrα1, Gfrα2, and Gfrα3) were 
designed using ABI software or found in PrimerBank and are listed in Table 2. Primer sets for 
60S ribosomal protein L13A (Rpl13a) were from a mouse housekeeping genes primer set 
(MHK-1; RealTimePrimers.com, Elkins Park, PA) and Rpl13a expression was used as a 
reference standard for analysis of gene expression in the pancreas (Table 3). Relative fold 
changes in RNA level was calculated using the ∆∆Ct method257.  Significance was determined 
using Mann-Whitney U-tests (SPSS Statistics). Additional potential normalization genes from 
MHK-1[β-actin (Actb), β2-microglobulin (B2m), β-glucuronidase (Gusb), hypoxanthine 
phosphoribosyl-transferase1 (Hprt1), phosphoglycerokinase (Pgk), and cyclophilinA (Ppia)] 
were screened as potential reference standards and expression of each was found to be 
significantly increased in the pancreas of PDAC mice as compared to controls.  Primer sets for 
MHK-1 transcripts are listed in Table 3.   
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Table 3.  Primer sequences for murine normalization genes for qRT-PCR 
Gene Forward (5’ 3’) Reverse (5’ 3’) 
Actb AAGAGCTATGAGCTGCCTGA TACGGATGTCAACGTCACAC 
B2m GGCCTGTATGCTATCCAGAA GAAAGACCAGTCCTTGCTGA 
Gusb AATGAGCCTTCCTCTGCTCT AACTGGCTATTCAGCTGTGG 
Hprt1 GCTGACCTGCTGGATTACAT TTGGGGCTGTACTGCTTAAC 
Pgk GCAGATTGTTTGGAATGGTC TGCTCACATGGCTGACTTTA 
Ppia AGCTCTGAGCACTGGAGAGA GCCAGGACCTGTATGCTTTA 
Rpl13a ATGACAAGAAAAAGCGGATG CTTTTCTGCCTGTTTCCGTA 
 
2.10 PANCREATIC CANCER CELL LINES   
Transcriptional profiling of human tumor-derived cell lines (MiaPaCa2 and Panc1; ATCC, 
Manassas, VA) and murine tumor-derived cell lines (Kpc1 and Kpc2) was carried out. Murine 
cell lines were derived from tumors from two different PDAC mice (p48-Cre; LSL-KrasG12D; 
p53Lox/Lox), dissociated in the laboratory of Dr. Herbert J. Zeh III, chief of the Division of 
Gastrointestinal Surgical Oncology, UPMC262, and cultured in RPMI media (Gibco, Life 
Technologies, Grand Island, NY) with 10% FBS and 1% Pen/Strep.  MiaPaCa2 cells were 
cultured in MEM (Gibco, Life Technologies, Grand Island, NY) with 10% FBS, 1% Pen/Strep, 
and 2.5% horse serum (HS; Gibco, Invitrogen, Grand Island, NY).  Panc1 cells were cultured in 
MEM with 10% FBS and 1% Pen/Strep.  Cell lines were grown to confluence on a 100mm plate 
and RNA was collected in 1mL of Trizol reagent, extracted with 200µl chloroform, precipitated 
in 800µl isopropanol, rinsed with 75% EtOH, and reconstituted in RNase-free water.  5 µg of 
RNA from each cell line was treated with DNAse and 1µg of DNAsed RNA was reverse-
transcribed using Superscript II.  PCR amplification of 40ng of cDNA was done using GoTaq 
DNA polymerase (Promega, Madison, WI) and samples were separated by gel electrophoresis on 
a 2% agarose gel with ethidium bromide (0.5μg/ml), in TAE buffer.  Primer sets for mouse Ngf, 
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Artn, Gdnf, Bdnf, Nrtn, Trka, Gfrα3, Gfrα1, Trkb, Gfrα2, and Gapdh are list in Table 2.  Primer 
sets for human NGF, ARTN, GDNF, BDNF, NRTN, TRKA, GFRα3, GFRα1, TRKB, GFRα2, and 
GAPDH were designed using ABI software or found in PrimerBank and are listed in Table 4.   
 
 
 
Table 4.  Human primer sequences for RT-PCR 
Gene Forward (5’ 3’) Reverse (5’ 3’) 
ARTN GCACCCCCATCTGCTCTTCC CAGGCTGAGGTCGTGTGGAG 
BDNF TCCACCAGGTGAGAAGAGTGATG TCACGCTCTCCAGAGTCCCATG 
GAPDH TGACAACTTTGGTATCGTGGAAGG AGGCAGGGATGATGTTCTGGAG 
GDNF GGCAGTGCTTCCTAGAAGAGA AAGACACAACCCCGGTTTTTG 
GFRα1 CCAAAGGGAACAACTGCCTG CGGTTGCAGACATCGTTGGA 
GFRα2 CCAGCGAGTACACCTACCG TCCTTGTCCTCATAGGAGCAG 
GFRα3 GCCTGCTTGGACATCTATTGGA CAGCCGGTCACACTTGTCAT 
NGF GGCAGACCCGCAACATTACT CACCACCGACCTCGAAGTC 
NRTN CTCCGTGCTGTCCATCTG CAGCTCCATCGCATCCG 
TRKA GTCAGCCACGGTGATGAAATC CAGCACGTCACGTTCTTCCT 
TRKB ACCCGAAACAAACTGACGAGT AGCATGTAAATGGATTGCCCA 
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3.0  RESULTS 
3.1 DISEASE PROGRESSION  
3.1.1 Observed course of illness 
Neuroplastic changes associated with PDAC were studied using genetically engineered PDAC 
mice that express a conditional mutant Kras allele and a Trp53 allele with LoxP sites under 
control of a pancreas-specific promoter (Ptf1a-p48) driving Cre (p48-Cre).  In order to visualize 
pancreas-derived cells throughout the body, PDAC mice were crossed with a tdTomato reporter 
strain (Gt(ROSA)26SortdTomato ) to produce tPDAC mice.  Beginning at postnatal day 28, all mice 
were weighed weekly to monitor for illness-related weight loss. However, no significant 
difference in weight between cancer mice and age- and sex-matched littermates was detected 
(Figure 1).       
Along with weekly weight measurement, cancer mice were screened for the development 
of cancer-related sequelae such as abdominal distention due to ascites or jaundice secondary to 
biliary tree obstruction. Although age provided an approximation of disease progression in 
PDAC and tPDAC mice, significant variability in tumor size, tumor location, and sickness 
severity was observed, particularly in animals greater than 16 (> 16) weeks of age.  Disease 
progression and sickness severity was therefore assessed using a hunching scale adapted from a 
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previous study of pancreatic acinar carcinoma in the mouse 223,224 described in 2.2 SICKNESS 
AND HUNCHING ASSESSMENT.  Animals were scored weekly starting at post-natal day 28 
and the average age that a hunching score of 1 was first detected in PDAC mice was 10 weeks, 
which correlated with a PanIN-only stage of tumor development.  A hunching score of 2 or 3 
correlated with significant sickness and was detected as early as 19 weeks and as late as 26 
weeks, at which point animals had significant tumor burden.  A hunching score of 4 correlated 
with terminal disease and animals were euthanized.    
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Figure 1.  Weight gain in male and female PDAC and control mice 
 
Weight increased in all groups with age and no significant difference in weight gain was 
observed between PDAC mice and age- and sex-matched littermate controls.  The number of 
mice for each group ranged from 1 to 36 depending on age.  Error bars represent SEM.   
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3.1.2 Gross anatomical changes  
Although mutations in Kras and Trp53 are present at birth in PDAC mice (including tPDAC 
mice), pancreata of PDAC and tPDAC mice at 3-4 and 6-8 weeks of age appeared grossly 
normal when resected for histological and RNA studies.  At 10-12 weeks of age, the pancreas of 
some PDAC and tPDAC mice had a nodular appearance not evident in age-matched control mice 
(not shown).  While disease course was variable among PDAC and tPDAC mice, large nodular 
tumors were observed in most mice by 16 weeks (Figure 2). The time to tumor development 
observed in our studies is consistent with prior reports using related mouse strains89,117,254.  At 
later time points in disease progression (typically >20 weeks), local tumor spread to 
retroperitoneal structures, encasement or invasion of adjacent organs such as the duodenum, 
tumor invasion throughout peritoneum, and distant metastases to the liver and occasionally the 
lungs were grossly visible (Figure 2B).  In many PDAC mice, dilatation of the common bile 
duct and/or gall bladder enlargement was evident, likely a result of tumor-related biliary tree 
obstruction (not shown).   
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Figure 2.  In situ appearance of advanced PDAC 
 
The pancreas is located just below the stomach and first segment of the duodenum in control 
mice (A).  A large, nodular, and fibrotic tumor is adherent to the stomach and duodenum and 
extends throughout the peritoneum in a 26.5 week-old PDAC mouse with advanced disease.  
Metastases to the liver (labeled liver mets) are grossly visible (B).     
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3.1.3 Histological changes associated with disease progression  
At the time of weaning at postnatal day 21, the pancreas of PDAC mice appears histologically 
normal (Figure 3A).  Pre-malignant pancreatic intraepithelial neoplasia (PanIN) lesions 
(typically scored as PanIN-1a or -1b), focal fibrosis, and occasionally acute pancreatitis are 
present in the pancreas of 6-8 week old PDAC mice (Figure 3B).  By 10-12 weeks of age, 
multifocal PanIN lesions ranging from PanIN-1A to -3, more extensive focal fibrosis, chronic 
inflammation, and regions of pancreas with histological changes resembling descriptions of 
lobular atrophy in human PDAC tissue 77 are evident (Figure 3C).   Typically, pancreatic ductal 
adenocarcinoma was histologically evident in the pancreas of PDAC mice by 16 weeks of age 
and a significant desmoplastic component of the tumor with was observed in many cases of 
advanced disease (Figure 3D).  Chronic inflammation and extinction of the background pancreas 
was also observed in PDAC mice with advanced disease.  Because the conditional mutant alleles 
are expressed in every cell of pancreatic origin, PDAC mice often displayed multifocal 
pancreatic disease.  Therefore, PDAC mice had multiple regions of PanIN lesions at pre-
malignant time points (6-8 and 10-12 weeks) and regions of both cancer and PanIN at later time 
points (>16 weeks).  The presence of multifocal disease in this model likely contributed to the 
variability in disease course and survival time observed in PDAC and tPDAC mice.   
In tPDAC mice, all cells of pancreatic origin are tdTomato+ (Figure 4).  As regions of 
fibrosis and acinar atrophy develop (6-8 weeks) and expand (10-12 and >16 weeks), regions of 
pancreas parenchyma are replaced with tdTomato negative stroma (Figure 4B-D).  Metastatic 
tumor cells, also of pancreatic origin, in the liver and lung are also tdTomato+ (Figure 5).        
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Figure 3.  Histological changes in the pancreas of PDAC mice 
 
Representative H&E stained sections of pancreas from PDAC mice demonstrate the progression 
from PanIN lesions and fibrosis to PDAC.  The pancreas of PDAC mice appears histologically 
normal at 3-4 weeks of age (A).  By 6-8 weeks of age, focal fibrosis and mild PanIN lesions 
(outlined by red dashed lines) are evident (B). Regions of healthy pancreas (arrow) are 
surrounded by extensive lobular fibrosis and multifocal PanIN lesions in PDAC mice at 10-12 
weeks of age (C).  Ductal adenocarcinoma with a large desmoplastic component is histologically 
evident in the pancreas of PDAC mice >16 weeks of age (D).              
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Figure 4.  Changes in tdTomato expression in the pancreas of tPDAC mice 
 
All cells of pancreatic origin express the red fluorescent protein tdTomato in tPDAC mice.  
However, regions of focal fibrosis (outlined by white dashed lines in B) that develop starting at 
6-8 weeks of age (B) and expand into regions of lobular atrophy and fibrosis (outlined by white 
dashed lines in C) by 10-12 weeks of age (C) are tdTomato-negative.  This leads to the 
progressive extinction of tdTomato fluorescence as background pancreas is replaced by 
desmoplastic reaction in tPDAC mice with advanced disease (D).   
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Figure 5.  Metastatic disease in the liver and lung of tPDAC mice 
 
H&E stained sections of liver (A) and lung (C) demonstrate the appearance of distance 
metastases present in some PDAC mice with advanced disease (>16 weeks of age).  Metastatic 
tumor cells of pancreatic origin express tdTomato in the liver (B) and lung (D).   
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3.2 PAIN-RELATED BEHAVIOR  
3.2.1 Decreased open-field exploratory activity 
To assess the effects of PDAC-related pain on mouse behavior, we analyzed open-field 
exploratory activity throughout disease progression (7-31 weeks of age) using photoelectric 
monitoring.  The change in horizontal movement along the floor of the behavior arena over time 
was not significantly different between PDAC and control mice (Figures 6-9).  Measurements of 
horizontal movement included velocity of movement (Velocity; Figure 6), time spent moving 
(Move Time; Figure 7), distance travelled (Distance; Figure 8), and total number of movements 
(Moves; Figure 9).  These behavior measurements were relatively consistent across animal age 
for both PDAC and control mice.   In contrast, the change in vertical movement in which the 
animals are extending or rearing upward was significantly different between PDAC and control 
mice, with activity decreasing over time for many PDAC mice but not controls (Figures 10-13).  
Measurements of vertical movement included the number of vertical extensions (Extensions, p= 
0.0014; Figure 10), the amount of time spent extending vertically (Time, p= 0.0006; Figure 11), 
distance travelled while extending vertically (Distance, 0.0099; Figure 12), and the number of 
movements made while extending vertically (Moves, p= 0.0311; Figure 13).  Measurements of 
vertical movement include postural movements like rearing, but also included more subtle 
movements in which the mouse dorsiflexed its neck.  One aspect that these vertical 
measurements have in common is elongation of the trunk, a movement that conflicts with the 
progressively hunched postures adopted by these animals as the disease progresses and with the 
pain-related hunching described in a mouse model of pancreatic acinar carcinoma 223,224. 
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Figure 6.  Velocity of horizontal movement by PDAC and control mice over time      
 
The velocity of horizontal movements along the floor of the open-field testing arena was 
measured in PDAC and control mice over time.  Data from the 15-minute testing period were 
divided into three 5-minute blocks (Blocks 1-3).  Black lines represent the change in activity for 
individual animals over time and red lines represent the mean change in activity over time for the 
group.  The change in behavior over time was relatively consistent across Blocks 1-3 and no 
significant difference in the change in velocity of horizontal movements over time was found 
between PDAC and control mice.  Control n= 80, PDAC n= 66.        
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Figure 7.  Time spent moving horizontally by PDAC and control mice over time 
 
The time spent moving horizontally along the floor of the open-field testing arena was measured 
in PDAC and control mice over time.  Data from the 15-minute testing period were divided into 
three 5-minute blocks (Blocks 1-3).  Black lines represent the change in activity for individual 
animals over time and red lines represent the mean change in activity over time for the group.  
The change in behavior over time was relatively consistent across Blocks 1-3 and no significant 
difference in the change in time spent moving horizontally over time was found between PDAC 
and control mice.  Control n= 80, PDAC n= 66.   
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Figure 8.  Distance travelled horizontally by PDAC and control mice over time 
 
The distance travelled horizontally along the floor of the open-field testing arena was measured 
in PDAC and control mice over time.  Data from the 15-minute testing period were divided into 
three 5-minute blocks (Blocks 1-3).  Black lines represent the change in activity for individual 
animals over time and red lines represent the mean change in activity over time for the group.  
The change in behavior over time was relatively consistent across Blocks 1-3 and no significant 
difference in the change in distance travelled horizontally over time was found between PDAC 
and control mice.  Control n= 80, PDAC n= 66.       
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Figure 9.  The number of horizontal movements by PDAC and control mice over time 
 
The total number of horizontal movements along the floor of the open-field testing arena was 
measured in PDAC and control mice over time.  Data from the 15-minute testing period were 
divided into three 5-minute blocks (Blocks 1-3).  Black lines represent the change in activity for 
individual animals over time and red lines represent the mean change in activity over time for the 
group.  The change in behavior over time was relatively consistent across Blocks 1-3 and no 
significant difference in the change in the number of horizontal movements over time was found 
between PDAC and control mice.  Control n= 80, PDAC n= 66.    
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Figure 10.  The number of vertical extensions made by PDAC mice decreases over time 
 
The number of vertical extensions made was measured in PDAC and control mice over time.  
Data from the 15-minute testing period were divided into three 5-minute blocks (Blocks 1-3).  
Black lines represent the change in activity for individual animals over time and red lines 
represent the mean change in activity over time for the group.  The change in behavior over time 
was relatively consistent across Blocks 1-3. There was a significant difference in the change in 
number of vertical extension made over time between PDAC and control mice. ** p< 0.01.  
Control n= 80, PDAC n= 66.   
** ** ** 
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Figure 11.  Time spent extending vertically decreases over time in PDAC mice   
 
The amount of time spent extending vertically was measured in PDAC and control mice over 
time.  Data from the 15-minute testing period were divided into three 5-minute blocks (Blocks 1-
3).  Black lines represent the change in activity for individual animals over time and red lines 
represent the mean change in activity over time for the group.  The change in behavior over time 
was relatively consistent across Blocks 1-3. There was a significant difference in the change in 
the amount of time spent extending vertically over time between PDAC and control mice. 
 *** p< 0.001.  Control n= 80, PDAC n= 66.    
   
*** *** *** 
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Figure 12.  Distance travelled while extending vertically decreases over time in PDAC mice   
 
The distance travelled while extending vertically was measured in PDAC and control mice over 
time.  Data from the 15-minute testing period were divided into three 5-minute blocks (Blocks 1-
3).  Black lines represent the change in activity for individual animals over time and red lines 
represent the mean change in activity over time for the group.  The change in behavior over time 
was relatively consistent across Blocks 1-3. There was a significant difference in the change in 
distance travelled while extending vertically over time between PDAC and control mice.  
** p< 0.01.  Control n= 80, PDAC n= 66.      
** ** ** 
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Figure 13.  The number of movements made while extending vertically decreases over time in PDAC mice 
 
The number of movements made while extending vertically was measured in PDAC and control 
mice over time.  Data from the 15-minute testing period were divided into three 5-minute blocks 
(Blocks 1-3).  Black lines represent the change in activity for individual animals over time and 
red lines represent the mean change in activity over time for the group.  The change in behavior 
over time was relatively consistent across Blocks 1-3. There was a significant difference in the 
change in number of movements made while extending vertically over time between PDAC and 
control mice.  *p< 0.05.  Control n= 80, PDAC n= 66.   
* * * 
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Behavior data were also binned into discreet age ranges corresponding to time points in 
disease progression (6-8 weeks, 10-12 weeks, and >16 weeks), however there was no significant 
effect of age or genotype nor was there a significant interaction for any of the horizontal 
movement measurements (Table 5) or vertical movement measurements (Table 6).  When the 
data were filtered into discreet age ranges, the number of mice included in the analyses for each 
group was relatively small and may have made detection of significant effects difficult.  
Additionally, substantial variability in PDAC mouse behavior over time was observed in 
measurements of horizontal and vertical movements.  This variability was most pronounced after 
16 weeks of age and is likely related to the variable disease course observed in PDAC mice with 
cancer. 
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Table 5.  Horizontal open-field exploratory activity in PDAC and control mice 
Horizontal Behavior Measurements 
            6-8 weeks 10-12 weeks >16 weeks 
Velocity Control  2.66 ± 0.45     2.66 ± 1.26     2.76 ± 0.71 
(cm/sec)  PDAC  2.68 ± 0.61     3.22 ± 0.71     3.00 ± 1.23 
Move Time          220.56 ± 17.84 227.11 ± 19.81  229.38 ± 18.98  
(sec)          214.60 ± 17.16 234.00 ± 18.90  217.59 ± 39.17 
Distance          813.30 ± 140.45 814.96 ± 374.51  844.31 ± 210.99 
(cm)          818.00 ± 176.86 984.70 ± 215.29  916.45 ± 367.54 
Moves           47.88 ± 9.31 44.33 ± 8.85  42.47 ± 8.69 
(number)           48.20 ± 7.60 40.14 ± 8.32  43.48 ± 11.43 
 
 
Measurements of horizontal open-field exploratory activity in PDAC (red) and control (blue) 
mice were analyzed at three different time points corresponding to stages of disease progression: 
6-8 weeks, early PanIN stage; 10-12 weeks, moderate to severe PanIN stage; >16 weeks, PDAC 
stage. There were no significant differences between PDAC and control mice at any age.  Data 
from the 15-minute testing period were divided into three 5-minutes blocks and data from Block 
2  (mean ± standard deviation) are presented as representative.  Control n= 16 (6-8 weeks), n= 9 
(10-12 weeks), and n= 55 (>16 weeks).  PDAC n= 5 (6-8 weeks), n= 7 (10-12 weeks), and n= 54 
(>16 weeks).    
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Table 6.  Vertical open-field exploratory activity in PDAC and control mice 
Vertical Behavior Measurements 
                   6-8 weeks 10-12 weeks      >16 weeks 
Extensions Control  43.69 ± 12.41 48.78 ± 10.21    42.93 ± 13.28 
(number) PDAC   42.40 ± 9.71 46.57 ± 8.30    42.39 ± 18.01 
Time               94.75 ± 24.90 91.33 ± 16.87    96.62 ± 38.42 
(sec)               89.80 ± 24.45 77.57 ± 13.60    87.48 ± 41.60 
Distance               58.54 ± 22.16 40.12 ± 18.19    73.58 ± 69.91 
(cm)              48.06 ± 19.61 36.20 ± 18.53    55.89 ± 45.12 
Moves            39.94 ± 7.06 44.22 ± 5.19   37.85 ± 8.82 
(number)            38.00 ± 6.74 40.57 ± 7.63    36.04 ± 12.80 
 
 
Measurements of vertical open-field exploratory activity in PDAC (red) and control (blue) mice 
were analyzed at three different time points corresponding to stages of disease progression: 6-8 
weeks, early PanIN stage; 10-12 weeks, moderate to severe PanIN stage; >16 weeks, PDAC 
stage.  There were no significant differences between PDAC and control mice at any age.  Data 
from the 15-minute testing period were divided into three 5-minutes blocks and data from Block 
2 (mean ± standard deviation) are presented as representative.  Control n= 16 (6-8 weeks), n= 9 
(10-12 weeks), and n= 55 (>16 weeks).  PDAC n= 5 (6-8 weeks), n= 7 (10-12 weeks), and n= 54 
(>16 weeks). 
 
 
 
 
 
 
 
 
 65 
3.2.2 Endogenous opioids in pain-related behavior  
Open-field exploratory activity, specifically when involving movements that require reaching 
vertically, decreases with age in PDAC mice.  We hypothesized that this change in behavior was 
reflective of PDAC-associated pain.  A previous study of cancer pain in a mouse model of 
pancreatic acinar carcinoma demonstrated that mice with cancer treated with naloxone exhibited 
more pain-related behavior than mice treated with saline224, suggesting that endogenous opioid 
signaling attenuates early cancer-related pain.  To determine if a similar opioid-based mechanism 
occurs in PDAC mice, we tested whether blocking endogenous opioid signaling with naloxone 
treatment 30 minutes before behavior monitoring “un-masked” pain-related behavior in these 
mice.  Mice were 17-31 weeks of age and PDAC mice had hunching scores of 1 or 2 at the time 
of testing.  While open-field exploratory activity decreased substantially in some mice treated 
with naloxone (Figures 14 and 15), there was no significant difference between PDAC and 
control groups in the number of mice that demonstrated decreased activity for any of the 
behavior measurements.  Neither age nor sex was significantly correlated with decreased 
exploratory activity following naloxone administration (data not shown). Percent change in 
behavior from baseline following naloxone administration was compared between PDAC and 
control mice, however no significant differences were observed in horizontal movement 
measurements (Table 7) or vertical movement measurements (Table 8).     
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Figure 14.  Effects of naloxone on horizontal open-field exploratory activity in PDAC and control mice 
 
Horizontal open-field exploratory activity was measured at baseline, 23.5 hours later 4mg/kg 
naloxone was administered subcutaneously, and horizontal open-field exploratory activity was 
measured 30 minutes later (24 hours after baseline measurements were collected).  Data from the 
two 15-minute testing periods were divided into three 5-minutes blocks, and change in behavior 
from baseline following naloxone treatment was relatively constant across time block.  There 
was significant variability in post-naloxone behavior among control (blue) and PDAC (red) 
mice, however, there was no significant difference between the two groups in the number of 
mice demonstrating decreased horizontal behavior following naloxone treatment.  
Control n= 9, PDAC n= 10       
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Figure 15.  Effects of naloxone on vertical open-field exploratory activity in PDAC and control mice 
 
Vertical open-field exploratory activity was measured at baseline, 23.5 hours later 4mg/kg 
naloxone was administered subcutaneously, and horizontal open-field exploratory activity was 
measured 30 minutes later (24 hours after baseline measurements were collected).  Data from the 
two 15-minute testing periods were divided into three 5-minutes blocks, and change in behavior 
from baseline following naloxone treatment was relatively constant across time block.  There 
was significant variability in post-naloxone behavior among control (blue) and PDAC (red) 
mice, however, there was no significant difference between the two groups in the number of 
mice demonstrating decreased vertical behavior following naloxone treatment.  
Control n= 9, PDAC n= 10.   
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Table 7.  Percent change in horizontal open-field exploratory activity after naloxone treatment  
Horizontal Behavior Measurements 
    Block 1            Block 2           Block 3 
Velocity Control   -3.39% ± 14.08 -4.27% ± 28.58 -17.24% ± 25.39 
(cm/sec) PDAC   -5.92% ± 18.50 -17.36% ± 24.16 -28.85% ± 20.47 
Move Time              -6.45% ± 14.92 -7.02% ± 11.96 -11.37% ± 14.23 
(sec)              -5.50% ± 11.20 -8.00% ± 17.70 -15.39% ± 16.34 
Distance              -3.28% ± 13.75 -3.71% ± 28.04 -16.18% ± 25.21 
(cm)              -5.29% ± 18.69 -17.27% ± 23.60 -28.16% ± 20.64 
Moves             17.55% ± 20.35 12.93% ± 18.38 20.83% ± 20.91 
(number)             15.10% ± 16.69 9.18% ± 18.67 20.06% ± 28.53 
 
 
Data from the 15-minute baseline and post-naloxone testing periods were divided into three 5-
minute time blocks.  Data presented are mean percent change score [(post-naloxone treatment – 
baseline)/baseline] ± standard deviation for control (blue) and PDAC (red) mice for each time 
block.  There were no significant differences in percent change in behavior after naloxone 
treatment between the two groups for any of the horizontal behavior measurements.   
Control n= 9, PDAC n= 10.        
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Table 8.  Percent change in vertical open-field exploratory activity after naloxone treatment  
Vertical Behavior Measurements 
       Block 1            Block 2            Block 3 
Extensions Control  -38.56% ± 26.75 -41.28% ± 15.84 -44.20% ± 18.26 
(number) PDAC  -28.33% ± 36.42 -41.05% ± 32.54 -36.24% ± 29.10 
Time             -31.43% ± 28.15 -39.82% ± 18.27 -34.04% ± 24.88 
(sec)             -19.14% ± 38.68 -35.68% ± 34.80 -33.54% ± 28.93 
Distance             -33.72% ± 41.79 -53.57% ± 20.12 -51.82% ± 24.99 
(cm)            -30.83% ± 33.63 -51.95% ± 33.92 -51.60% ± 20.35 
Moves            -29.39% ± 27.20 -29.44% ± 18.73 -33.07% ± 22.98 
(number)            -22.55% ± 28.95 -31.04% ± 31.63 -28.88% ± 29.63 
 
 
Data from the 15-minute baseline and post-naloxone testing periods were divided into three 5-
minute time blocks.  Data presented are mean percent change score [(naloxone-treated – baseline 
activity)/baseline activity] ± standard deviation for control (blue) and PDAC (red) mice for each 
time block.  There were no significant differences in percent change in behavior after naloxone 
treatment between the two groups for any of the vertical behavior measurements.   
Control n= 9, PDAC n= 10. 
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3.3 TUMOR-NERVE INTERACTIONS  
3.3.1 Neuroplastic changes  
Neuroplastic changes are commonly described in sections of resected tumor from late-stage 
PDAC patients136,263 and these changes in innervation frequently include perineural tumor 
invasion129,130,132.  Transgenic mouse models of PDAC provide an excellent model in which to 
examine the temporal dynamics of changes in pancreas innervation and perineural invasion 
throughout PDAC disease progression.   I therefore used the pan-neuronal marker PGP 9.5 to 
determine when changes in pancreatic nerve fibers occur in PDAC mice.  At 6-8 weeks of age, 
tPDAC pancreata exhibited small areas of hyperinnervation not present in control pancreata 
(Figure 16A-H).  These areas were restricted to regions containing fibrosis, acinar atrophy, 
and/or PanIN lesions, whereas innervation in histologically normal pancreas was similar to that 
of controls.  In the pancreas of tPDAC mice at 10-12 weeks of age, there were significantly more 
lobules of pancreas with abnormal pathology and multifocal PanIN lesions ranging from 
PanIN1A to PanIN3, and increased hyperinnervation accompanied this expansion of pancreas 
pathology (Figure 16I-L).  
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Figure 16.  Distribution of PGP9.5- positive fibers during PDAC development 
 
Only occasional thin PGP 9.5-positive fibers are observed (arrows) within the parenchyma of the 
pancreas (indicated by tdTomato expression) in control mice (A-D).  By 6-8 weeks, numerous 
PGP-positive fibers (arrow) can be seen associated with blood vessels and dilated ducts in 
regions of focal fibrosis (E-H).  Dotted lines indicate border between fibrotic region and normal 
appearing pancreas (G).  Significant areas of fibrosis containing dense innervation by PGP-
positive fibers are present in the pancreas of PDAC mice at 10-12 weeks (I-L).  Dotted lines in 
(K) indicate region lobular fibrosis.  Calibration bar = 50µm.   
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Large intrapancreatic nerve bundles in areas of hyperinnervation were observed in PDAC 
pancreata/tumors at >16 weeks of age (Figure 17).  Hypertrophied nerves were often associated 
with areas of lobular fibrosis and acinar cell atrophy (Figure 17D, H, L). PGP+ fibers were 
visualized extending from atrophied/aggregated islets (Figure 17A-D), near ducts and 
vasculature (Figure 17E-K), and adjacent to areas of PanIN lesions or tumor cells (Figure 17I-
L).  Hypertrophied fibers observed in the pancreas of older PDAC mice (10-12 and > 16 weeks) 
were CGRP+ (Figure 18) and TH+ (Figure 19), suggesting involvement of both sensory and 
sympathetic pancreatic nerves, respectively.   
3.3.2 Perineural invasion in PDAC 
Though documented in human PDAC55, instances of intra- or extra-pancreatic perineural tumor 
invasion have not been previously described in transgenic mouse models of PDAC.  Therefore, 
we used tPDAC mice to determine whether PNI or tdTomato+ cells of pancreatic origin in local 
and distant sensory and sympathetic nerve ganglia could be detected.  While intra-pancreatic PNI 
was not definitively observed, areas of focal fibrosis with hyperinnervation often featured 
branching of PGP9.5+ fibers near the remaining tdTomato+ cells, suggesting the tropism between 
the two.   In one case, tdTomato+ cells were present and appeared to be forming “pseudo ducts” 
inside the celiac ganglion (Figure 20), which was surrounded by a large tumor metastasis.  In 
this case, many of the celiac ganglion cells were positive for ATF3+, a marker of nerve injury 
only rarely expressed in control celiac ganglion cells (Figure 20D-F, arrows in 20D).   
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Figure 17.  Examples of abnormal innervation in PDAC mice with identifiable tumors 
 
 
Hypertrophied nerves with multiple branching fibers are present, primarily in regions with 
fibrosis and loss of acinar cells, as indicated by overlap of PGP 9.5 and loss of tdTomato-
expressing cells.  In some cases fiber bundles can be seen extending from atrophied/aggregated 
islets (A-D), associated with ducts or vasculature (E-H), and adjacent to areas of PanIN lesions 
or tumor cells (I-L).  Arrow in (C) shows nerve fibers appearing to engulf tdTomato-positive 
cells.  Calibration bar = 50µm     
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Figure 18.  CGRP-positive nerve fibers in PDAC mice 
 
Numerous CGRP-positive fibers are present in areas of pancreas with PanIN lesions and fibrosis 
in PDAC mice at 10-12 (A-C) and >16 (D-F) weeks of age. 
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Figure 19.  TH-positive nerve fibers in PDAC mice 
 
Numerous TH-positive fibers are present in areas of pancreas with PanIN lesions and fibrosis in 
PDAC mice at 10-12 (A-C) and >16 (D-F) weeks of age.   
 
 
 
 
 
 
 
 
 
 
 
 
 76 
Figure 20.   PDAC induces pathological changes in the celiac ganglion 
 
Celiac ganglion neurons (arrows) immunostained with TH antibody (A).  tdTomato staining 
reveals extensive tumor growth around and within (arrows in C) the borders of the celiac 
ganglion (B-C).  The same celiac ganglion in (A-C) stained for expression of ATF3, a marker of 
neuronal injury (D-F).  Numerous ATF3-positive neuronal nuclei are seen throughout the 
ganglion (arrows in D).  Calibration bars A-C = 100µm; D-F = 50µm.   
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In a different tPDAC case, pancreas-derived cells invaded the dorsal T11 and T10 root 
ganglia (Figure 21 B-E). This migration of tumor cells into the DRG was associated with a 
metastatic tumor that surrounded the spinal cord at levels T9-T12 (Figure 21A), the levels of 
spinal cord that normally innervate the pancreas 256 Some pancreatic-derived cells in the DRG 
assumed complex morphology, exhibiting processes that could participate in cell-to-cell 
adhesion or chemotaxis (inset in Figure 21E).  Despite the large number of tdTomato+ cells 
present in the DRG, relatively few cells in the ipsi- or contralateral T10 and T11 DRG were 
ATF3+ (data not shown). 
3.3.3 Changes in sensory neuron gene expression  
Changes in pancreatic innervation induced in mouse models of acute and chronic pancreatitis are 
associated with changes in gene expression in associated sensory ganglia210,211.  We 
hypothesized that similar changes would be associated with the changes in pancreatic nerve 
fibers observed in PDAC mice.  The relative expression of genes related to nociception, 
neurogenic inflammation, and nerve injury was therefore analyzed in the T9-12 DRG, the 
ganglia shown to receive the most pancreatic sensory input256, of PDAC mice at ages 10-12 and 
>16 weeks.  Similar to changes described in mouse models of pancreatitis, expression of Trpa1 
and Trpv1 was significantly increased 1.74- and 1.36-fold, respectively, in the DRG of PDAC 
mice at >16 weeks of age (p=0.013 and p=0.043; Table 9).  In 10-12 week old PDAC mice, 
there was a non-significant trend toward increased Trpa1 expression (1.38-fold, p=0.059; Table 
9).   
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Figure 21.  Pancreas-derived tumor surrounding the spinal cord at the vertebral levels giving rise to sensory 
innervation in the pancreas 
Right and left arrows indicate T13 and T9 rib, respectively, demarcating the vertebral levels of 
the sensory ganglia that give rise to the majority of sensory innervation to the pancreas (A).  
Tumor, indicated by tdTomato expression, surrounds both dorsal (DR) and ventral (VR) roots of 
the right T11 DRG (B).  No tdTomato-positive cells are seen in this DRG.  Left T11 DRG 
containing numerous tdTomato-positive cells, presumably representing migrating tumor cells 
associated with the tumor formation (C).  Left T10 DRG stained with PGP 9.5 (D).  Merged 
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photomicrograph showing numerous tdTomato-positive cells interspersed between PGP 9.5-
positive DRG neurons (E).  tdTomato-positive cells were only seen in T10 and T11 DRG on the 
left side (C&E).  Insert in (E) shows a tdTomato–positive cell appearing to migrate between two 
DRG neurons.  Calibration bars A = 2mm; B&C = 100µm; C&D = 50µm.   
 
 
 
In rodent models of pancreatitis, TRPV1 and TRPA1 channels are implicated in neurogenic 
inflammation and release of neuropeptides such as CGRP and SP in the pancreas210,211,214,216,218 
(reviewed in137,207).  In line with this mechanism, the DRG of PDAC mice at both 10-12 and >16 
weeks of age also exhibited increased levels of Cgrp mRNA (1.36- and 1.27- fold, respectively 
(p=0.043 and p=0.029; Table 9).  In contrast, SP expression in the DRG was not significantly 
different between PDAC and control mice at 10-12 weeks and only a non-significant trend 
toward increased expression in PDAC DRG was apparent at >16 weeks of age (1.44-fold, p= 
0.081; Table 9).  Similarly, expression of Atf3, a marker of nerve injury, was not significantly 
different between control and PDAC DRG at 10-12 weeks, but a non-significant trend toward 
increased expression was evident at >16 weeks of age (1.92-fold, p= 0.059; Table 9).  In 
contrast, expression of the voltage-gated channels Nav1.8 and Kv4.3 was not significantly 
different in the DRG of control and PDAC mice at either age (Table 9).           
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Table 9.  Changes in sensory ganglia gene expression in PDAC mice 
Gene  10-12 weeks >16 weeks 
Atf3 1.22   (p=0.950) 1.92^  (p=0.059) 
Cgrp 1.36*  (p=0.043) 1.27*  (p=0.029) 
Kv4.3 0.99   (p=0.573) 1.00   (p=1.000) 
Nav1.8 1.12^  (p=0.081) 1.19   (p=0.282) 
SP 1.11   (p=0.662) 1.44^  (p=0.081) 
Trpv1 1.42   (p=0.142) 1.36*  (p=0.043) 
Trpa1 1.38^  (p=0.059) 1.74*  (p=0.013) 
 
Expression of genes related to injury, nociception, and neurogenic inflammation in DRG T9-12 
of PDAC mice.  Data are normalized using Gapdh as a reference standard and presented as fold 
change in expression relative to age-matched controls. Control n= 6, PDAC n= 8 for both age 
groups.  *p< 0.05;  ^ denotes a non-significant trend 
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3.3.4 Changes in evoked calcium transients in pancreatic sensory afferents  
Increased expression of Trpv1 and Trpa1 in pancreatic afferents in mouse models of acute and 
chronic pancreatitis were associated with an increased number of pancreatic afferents responding 
to application of TRP agonists, enhanced Ca2+ transients in pancreatic afferents in response to 
TRP channel agonists, and increased peak response to application of 50mM KCl210,211.  To 
determine if a similar change in TRP channel activation is associated with PDAC, pancreatic 
afferents in PDAC mice and controls were back-labeled with 1,1’-dioctadecyl-3,3,3’3’-
tetramethylindocarbocyanine perchlorate (DiI) and 8-10 days later, DRG T9-12 were removed 
bilaterally and dissociated to generate primary DRG cultures for Ca2+ imaging analyses as 
described in 2.8 PRIMARY DRG CELL CULTURE AND CALCIUM IMAGING.  Evoked 
Ca2+ transients in response to 50mM KCl (High K+) were measured in DiI+ cells and those not 
responding to High K+ (ΔF340/380 < 0.20) application were excluded from further analyses.  The 
percentage of pancreatic afferents responding to application of either the TRPV1 agonist 
capsaicin (1μM) or the TRPA1 agonist mustard oil (100μM) was measured for both PDAC and 
control mice at 6-8, 10-12, and >16 weeks of age.  The number of cells responding to either 
agonist (ΔF340/380 < 0.20) was not significantly different between cancer and control pancreas-
specific sensory neurons at any time point (Table 10).  However, analysis of peak percent 
change in ΔF340/380 from baseline following application of High K+ in pancreatic afferents of 
PDAC mice compared to control afferents revealed a significant age effect (F= 14.14, p<0.05) 
and a significant interaction between age and genotype (F= 3.02, p<0.05). Bonferroni post-tests 
revealed a non-significant trend toward increased peak percent change in ΔF340/380 from baseline 
in pancreatic neurons from PDAC mice at 10-12 weeks of age compared to pancreatic afferents 
from age-matched controls (p<0.07; Figure 22).   
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Table 10.  Percentage of pancreas-specific afferents responding to TRP channel agonists 
Capsaicin (1μM) 
 6-8 weeks 10-12 weeks >16 weeks 
Percent Control 43.06% ± 17.77 (27) 32.35% ± 12.49 (38) 64.77% ± 14.40 (33) 
Responders PDAC 63.34% ± 18.56 (27) 58.39% ± 11.52 (51) 62.63% ± 17.63 (40) 
Mustard Oil (100μM) 
 6-8 weeks 10-12 weeks >16 weeks 
Percent Control 66.00% ± 9.64 (33) 45.18% ± 19.08 (35) 47.23% ± 23.74 (28) 
Responders PDAC 85.55% ± 7.23 (54) 71.00% ± 8.27 (64) 73.03% ± 17.06 (36) 
 
 
Mean percentage (± standard error of the mean) of pancreas-specific afferents from control 
(blue) or PDAC (red) mice responding (ΔF340/380 < 0.20) to brief application of capsaicin (1μM) 
or mustard oil (100μM).  Number of cells in each group indicated in parentheses.  There were no 
significant differences in percentage of cells responding to either agonist between PDAC and 
control groups at any time point in PDAC development.        
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Figure 22.  Changes in evoked calcium transients in pancreatic sensory afferents 
 
Average peak percent change in ΔF340/380 from baseline following application High K+ for 
control (blue) and PDAC (red) pancreatic afferents.  Control n= 66 cells (6-8), n= 76 cells (10-
12), and n= 73 cells (>16).  PDAC n= 78 cells (6-8), n= 97 cells (10-12), and 58 cells (>16).  
Error bars represent standard error of the mean.  # non-significant trend, p<0.07.  
 
 
 
 
 
 
# 
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3.4 NEUROTROPHIC FACTOR EXPRESSION IN PDAC 
3.4.1 Changes in neurotrophic factor expression in the pancreas of PDAC mice 
Previous studies have associated increased neurotrophic growth factor expression with PDAC-
induced neuronal hypertrophy, perineural invasion and PDAC-related pain155–158,162 (reviewed 
in119,120,191).   Furthermore, increased neurotrophic factor expression during development or 
following inflammation has been shown to induce nerve sprouting and sensitization of primary 
sensory afferents as well as sympathetic efferents145–149,260.  To determine if changes occur in 
neurotrophic factors and their receptors during tumor development and progression, pancreas 
RNA collected from PDAC and control mice was analyzed at 3-4, 6-8, 10-12, and >16 weeks of 
age.  There were no significant differences in expression of Ngf, Gdnf, Bdnf, Artn, Nrtn or their 
receptors between PDAC and control mice at 3-4 weeks of age (Figure 23 and only Gfrα2, the 
receptor for Nrtn, was significantly increased (3.74 fold; p=0.008) in the pancreas of PDAC mice 
at 6-8 weeks (Figure 23). In the 10-12 week age group, Ngf, Trkb, Nrtn, and Gfrα2 were 
significantly increased (2.25-, 2.18-, 1.39-, and 3.42-fold, respectively; p= 0.007, p= 0.012, 
p=0.028, and p= 0.028) in the pancreas of PDAC mice (Figure 23).  In the pancreas of PDAC 
mice >16 weeks of age, Ngf, Trka, Gdnf, and Gfrα2 were significantly increased (3.6-, 29.9-, 
7.11-, and 4.02-fold, respectively; p= 0.03, p= 0.001, p= 0.023, and p= 0.024; Figure 23).  In 
contrast, Gfrα3 expression in the pancreas of >16 weeks old PDAC mice was significantly 
decreased (4.30-fold; p= 0.009; Figure 23).   
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Figure 23.  Increased neurotrophic factor and neurotrophic factor receptor expression in the pancreas of 
PDAC mice 
Expression of neurotrophic factors and neurotrophic factor receptors in the pancreas of PDAC 
mice was measured at 3-4, 6-8, 10-12, and >16 weeks of age, normalized using Rpl13a as a 
reference standard, and presented as the percent expression of age-matched controls. Control n= 
4 (3-4 weeks), n= 4 (6-8), n=5 (10-12), and n=6 (>16).  PDAC n= 6 (3-4), n=7 (6-8), n=7 (10-
12), and n=10 (>16).  *p<0.05; **p<0.01; ***p<0.001.  Data from >16 weeks old mice are also 
presented as the percent expression of controls normalized to the amount of cDNA amplified 
(>16Φ) and using this method of comparison, expression all neurotrophic factors and 
neurotrophic factor receptors except Gfrα3 is significantly increased, p<0.01.          
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For the transcriptional analyses above, gene expression was normalized to the 
housekeeping gene Rpl13a, which did not significantly change in PDAC mice at 3-4, 6-8, and 
10-12 weeks of age.  However, expression of Rpl13a was increased 3-fold in the pancreas of 
PDAC mice >16 weeks of age, as was the expression of seven other housekeeping genes (5- to 
15-fold; Table 11).  These changes suggest that as the tumor replaces normal pancreas 
parenchyma, fundamental changes in the tissue, including increases in rapidly dividing cells, 
occur producing an mRNA signature unique to PDAC.  It should also be mentioned that if 
mRNA expression is normalized based on the initial amount of cDNA amplified, larger and 
statistically significant changes in gene expression occur in all growth factors and receptors, 
except Gfrα3 (Figure 23).  Thus, regardless of the method used, significant changes in growth 
factor and receptor mRNA occur, indicating that as cancer progresses, the pancreas produces a 
milieu that resembles the pro-growth environment experienced by the peripheral nervous system 
during development. 
 
 
 
Table 11.  Changes in housekeeping gene expression in the pancreas of PDAC mice 
Expression of housekeeping genes in the pancreas 
of PDAC mice >16 weeks of age normalized to the 
amount of cDNA amplified and presented as fold 
change in expression relative to age-matched 
controls. N=4 for control and PDAC. 
Gene  >16 weeks 
Actb 15.24    
B2m 14.75 
Gapdh 14.14    
Gusb 5.23 
Hprt1 5.29 
Pgk 4.92    
Ppia 5.00 
Rpl13a 3.10 
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3.4.2 Neurotrophic factor and neurotrophic factor receptor expression in PDAC cell lines     
A variety of cell types including tumor cells, infiltrating immune cells, and cells in the stromal 
compartment of the tumor could each contribute to the observed changes in growth factor and 
growth factor receptor expression in the pancreas of PDAC mice.  Previous studies of human 
tumor cell lines have demonstrated that many express a variety of growth factors and receptors, 
suggesting that PDAC cells represent a significant source and target of released intrapancreatic 
neurotrophic factors.  To address the contribution of PDAC cells to changes in growth factor 
expression, RNA from two cell lines created from dissociated tumors of PDAC mice (Kpc1 and 
Kpc2) was analyzed to assess tumor-specific neurotrophic factor and neurotrophic factor 
receptor expression. Reverse transcriptase-PCR analysis showed that the Kpc1 and Kpc2 lines 
express Ngf, Artn, Gdnf, Nrtn, and Gfrα2 (Figure 24).  The Kpc2 line also expresses Gfrα3 and 
Gfrα1 (Figure 24).  The Kpc expression profile is quite similar to that of the two human tumor 
cell lines, Panc1 and MiaPaCa2, which express ARTN, BDNF, TRKA, GFRα3, and GFRα2 
(Figure 24).  Panc1 also expresses NGF, GFRα1 and TRKB while MiaPaCa2 also expresses 
GDNF (Figure 24).  These findings indicate that the growth factor-enriched environment of the 
pancreas during PDAC is generated, at least in part, from PDAC cells.  In addition, the 
development and progression of PDAC may be driven by both autocrine activation of growth 
factor receptors by growth factors released by tumor cells, and by paracrine activation of growth 
factor receptors by growth factors and inflammatory mediators released by stromal cells and/or 
infiltrating immune cells. 
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Figure 24.  Neurotrophic factor and neurotrophic factor receptor expression in PDAC cell lines 
 
RT-PCR analysis of gene expression in two murine PDAC cell lines (Kpc1 and Kpc2) and two 
human PDAC cell lines (MiaPaCa2 and Panc1).   
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4.0  DISCUSSION 
4.1 DISEASE PROGRESSION IN PDAC MICE PARALLELS HUMAN PDAC 
4.1.1 PDAC-related illness 
In patients with PDAC, common presenting signs and symptoms include jaundice, abdominal or 
epigastric pain, and weight loss1,3,42,62,65(reviewed in66–68).  As the disease progresses, patients 
may develop additional cancer sequelae such as anorexia, hepatomegaly, diabetes, cachexia, 
Courvoisier’s sign, presence of an abdominal mass, ascites, duodenal obstruction, and delayed 
gastric emptying3,62,69,73(reviewed in39).  In PDAC and tPDAC mice, several of the same signs 
were observed as tumor growth progressed.  Specifically, jaundice, bloody abdominal ascites, 
encasement of the duodenum, and enlarged gall bladder were all observed in the PDAC mouse 
cohort.  While PDAC mice generally weighed less than age-matched controls across all ages, no 
significant weight loss was observed.  In some cases, the development of abdominal ascites 
could have masked weight loss and/or cachexia associated with the cancer.  At later stages of the 
disease, PDAC mice adopt a rounded-back hunched posture that is likely related to the 
development of PDAC pain and may be analogous to PDAC patients who report that lying in a 
curled or fetal position reduces pain3.   
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The cohort of PDAC mice used for these studies resembles a clinical cohort of patients in 
that the collection of signs observed and the time course of disease progression were highly 
variable, particularly at later stages of disease.  Like human PDAC, some of the observed 
variability is likely due to differences in the genetic profiles of tumors in PDAC mice.  While all 
PDAC mice have mutations in Kras and loss of Trp53 expression, it is possible that additional 
mutations accumulate throughout tumor development and progression, influencing the observed 
disease course and tumor-related pathology.        
Unfortunately, early detection of PDAC is uncommon and often patients present with 
either locally invasive disease or distant metastases and are therefore not candidates for surgical 
resection1,38.  Local tumor spread typically includes retroperitoneal structures such as the aorta or 
superior mesenteric vessels as well as adjacent organs such as the duodenum1,38, while metastatic 
disease in PDAC most frequently affects the liver, peritoneum, and lungs (reviewed in39,74).  In 
PDAC mice, metastases to the peritoneum and liver were also most commonly observed, with 
occasional metastases to the lung. This suggests common mechanisms could underlie metastatic 
spread in human and mouse PDAC.  This commonality has particular importance for study the of 
tumor-nerve interactions as perineural tumor invasion is thought to be an important mode of 
disease spread.   
 
4.1.2 Tumor development and histology 
The studies of this dissertation focused on the neuroplastic changes that occur during the 
development and progression of cancer. Most cases of PDAC are thought to arise from pre-
malignant PanIN lesions that progress from low-grade dysplasia (PanIN-1A) to high-grade 
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dysplasia (PanIN-3) to invasive carcinoma75,76 (reviewed in74).  In transgenic mouse models of 
PDAC similar to the one used in this study, histological analysis of the pancreas of PDAC mice 
throughout tumor development demonstrates a progression from PanIN to PDAC117,243.  In this 
study, PanIN-1 lesions were evident in the pancreas of PDAC mice as early as 6-8 weeks of age, 
PanIN-2 or -3 lesions were present by 10-12 weeks of age, and PDAC typically developed by 16 
weeks of age.  An important distinction between mouse and human PDAC is the multifocal 
nature of disease in PDAC mice.  Because the pancreas-specific mutations expressed in PDAC 
mice are in all cells of pancreatic origin, multifocal PanIN lesions and multiple tumor loci 
develop in PDAC mice.  Other PDAC features such as lobular atrophy, similar to what has been 
described in the pancreas of patients at high risk of developing PDAC77, and the dense, stromal 
fibrosis or desmoplastic reaction prominent in human PDAC were also observed in the pancreas 
of PDAC mice.  Overall, tumor development in PDAC mice closely models human PDAC, 
providing a useful tool to examine the development of cancer-related neuroplastic changes. 
4.2 CANCER-RELATED PAIN IN MICE PARALLELS PAIN IN HUMAN PDAC 
4.2.1 PDAC pain presents in late stages of disease  
Abdominal or epigastric pain is a common presenting symptom in patients with PDAC, however 
this frequently correlates with late stage disease1,3 (reviewed in66–68).  The late onset of 
symptoms such as pain largely explains why early detection of pancreatic cancer is rare.  Pain is 
also one of the most commonly reported symptoms in PDAC patients, with up to 80% of patients 
reporting pain by end stage disease136.  Interestingly, patient report of pain is not correlated with 
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tumor size or tumor location, but is associated with depression71,72, decreased quality of life71,72, 
and worse prognosis68,136.  This suggests that PDAC-related pain is not due solely to tumor mass 
and that pathological mechanisms underlying tumor development and progression affect 
pancreatic afferents as well. A better understanding of early neuroplastic changes in the pancreas 
during early stages of PDAC would provide valuable insight into mechanisms underlying cancer 
pain, which could lead to novel treatment strategies that improve the quality of life in PDAC 
patients.         
As experienced by patients with PDAC, pain-related behavior was observed in PDAC 
mice with increasing age and at later stages of disease.  Hunching behavior was evident at 10-12 
weeks, when moderate to severe PanIN lesions, but not PDAC were present. However, decreased 
open-field exploratory activity, particularly with regard to vertical movements, were not 
observed until later time points (> 16 weeks of age), when PDAC mice have a significant tumor 
burden.  With disease progression, PDAC mice adopt increasingly hunched postures when 
moving within their home cage, which is consistent with the decline in vertical movement 
measurements over with increased age.  While it is possible that the changes in exploratory 
activity are related purely to illness severity, the specificity of decreased activity only in vertical 
movements, which require the animals to extend their abdomens, but not in the horizontal 
movements where a hunched posture can be maintained, suggests increased desire to alleviate 
abdominal pain or discomfort.  The observation that pain-related behavior is most evident late in 
PDAC mice, after the progression from PanIN to PDAC, is consistent with previous studies of 
PDAC pain using a genetic mouse model of acinar carcinoma223,224. These finding suggest that 
the early, relatively restricted neuroplastic changes observed in tPDAC mice at pre-cancer stages 
are insufficient to cause pain, as measured by changes in animal posture and movement behavior. 
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Widespread hyperinnervation and associated changes in sensory afferent phenotype observed in 
tPDAC mice with PDAC may be necessary for detectable changes PDAC-related pain behavior. 
 
4.2.2 Endogenous mechanisms may attenuate PDAC-related pain 
The use of opioid analgesics may provide palliation for some patients with PDAC-related pain 
and a previous study of pain in a mouse model of pancreatic acinar carcinoma demonstrated 
reversal of pain-related hunching and vocalizations in mice following treatment with 
morphine223,224.  Furthermore, treatment with the CNS-penetrant opioid receptor antagonist 
naloxone to block endogenous opioid signaling “unmasked” pain-related hunching and 
vocalizations in this mouse model of acinar carcinoma224.  This suggests a role for opioid-
dependent mechanisms in modulation of PDAC-related pain.  In our study, we observed 
naloxone-induced attenuation of open-field exploratory activity in some PDAC mice, but a 
significant difference between cancer and control groups was not measured.  There was 
significant variability in response to naloxone treatment among PDAC mice, consistent with the 
varied disease course and survival time of the study cohort.  Given that some variability in 
response to naloxone was observed in control mice as well, experimental factors such as uniform 
injection of the full naloxone dose and habituation to the behavior box due to repeated testing in 
a 24-hour period could have also affected the observed behavior.  Differences in tumor burden, 
the genetic profile of the tumor, and the presence of local or distant metastases, or the presence 
or tumor-related sequelae such as bile duct obstruction could each contribute to differential 
responses to naloxone treatment among PDAC mice.  Additionally, there are patients with 
PDAC who never report cancer pain.  Therefore, there could be clinically important differences 
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between mice that develop PDAC-related pain early and are affected by naloxone treatment, and 
mice who develop pain at advanced stages of disease and are not affected by naloxone treatment 
early.     
4.3 CHANGES IN PANCREAS INNERVATION IN PDAC OCCUR EARLY IN 
DISEASE PROGRESSION 
4.3.1 Hyperinnervation in mouse and human PDAC 
Tumor-nerve interactions and hypertrophied nerve bundles in resected human PDAC tissue have 
been well documented118–121,136.  Hypertrophied nerve bundles are correlated with increased pain 
severity136 and may also provide an anatomical substrate for the extensive perineural tumor 
invasion observed in the disease. A previous study of pancreatic innervation in a mouse model of 
acinar carcinoma also demonstrated increased nerve density involving both sensory and 
sympathetic nerve fibers223.        
Innervation of the pancreas/tumor of tPDAC mice >16 weeks old was highly variable 
depending on the region of tumor examined.  In desmoplastic regions of the tumor with 
extinction of the background pancreas there were relatively few PGP9.5+ nerve fibers. These 
regions contrasted with areas of hyperinnervation where disorganized, torturous nerve fibers, 
similar in appearance to newly- sprouted nerve fibers, and hypertrophied fiber bundles were 
associated with tdTomato-positive cells.  These areas of hyperinnervation exhibited CGRP+ 
sensory fibers and TH+ sympathetic fibers. 
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Studies of neuroplastic changes in human PDAC are limited to a relatively small window 
in the late stages of disease in which most patients are diagnosed.  Having established that 
similar changes in pancreas and tumor innervation occur in PDAC mice at late stages of disease, 
it is reasonable to suggest that a similar process underlies the development of hyperinnervation in 
human and mouse PDAC during early, pre-malignant stages.  The parallels in PanIN to PDAC 
progression in mouse and human PDAC described above in 4.1.2 Tumor development and 
histology support this assertion.  Understanding the mechanisms that underlie the development 
of PDAC-related hyperinnervation may provide new targets for intervention to prevent such 
changes, which could attenuate both PDAC-related pain as well as disease progression.    
4.3.2 Hyperinnervation related to PDAC begins in pre-malignant stages of tumor 
development in PDAC mice 
We hypothesized that PDAC-related changes in pancreas innervation observed in advanced 
stages of human and mouse PDAC are not simply a consequence of the tumor, but rather 
represent a reciprocal relationship between the cancer and the peripheral nervous system that 
begins early in tumor development.  Because pre-malignant time periods are difficult to study in 
human PDAC, studies of neuroplastic changes in PDAC mice can provide valuable insight into 
the relationship between pancreas innervation and tumor progression.  As early as 6-8 weeks of 
age, areas of hyperinnervation are evident in the pancreas of tPDAC mice, typically in regions of 
focal fibrosis containing mild PanIN lesions. At 10-12 weeks, the expansion of focal fibrosis and 
progression from mild to moderate or severe PanIN are accompanied by increased innervation 
and, in some cases, large fiber bundles.  The appearance of hyperinnervation at these pre-
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malignant time points suggests that early changes in the microenvironment affect pancreatic 
nerves, potentially recruiting them as participants in disease progression.   
It is unknown whether the initial changes in the pancreas that result in the formation of 
PanIN lesions directly impact nerve fibers or whether cells in the microenvironment begin to 
express factors that may act on local pancreatic afferents.  The development of focal fibrosis and 
PanIN lesion formation could involve a variety of growth factors and cytokines and could also 
result in a microenvironment that is ischemic or acidic relative to normal pancreas.  Furthermore, 
it is possible that early changes in the microenvironment that drive pancreatic hyperinnervation 
also affect sensory afferent phenotype; resulting in sensitized afferents that could contribute to 
PDAC-pain and promote the transition from mild to severe PanIN and/or the expansion of 
fibrosis through neurogenic inflammation.   
4.4 CHANGES IN NEUROTROPHIC FACTOR AND NEUROTROPHIC FACTOR 
RECEPTOR EXPRESSION IN THE PANCREAS OF PDAC MICE OCCUR EARLY 
4.4.1 Neurotrophic factors in PDAC 
Studies from this laboratory and others have shown that neurotrophic factors enhance 
sprouting and sensitization of primary sensory afferents and sympathetic neurons in adult 
systems145–154.  Inflammatory mediators and growth factors identified in resected PDAC 
specimens are known to produce nerve hypertrophy, enhance neuron excitability, and promote 
perineural invasion136,155–158,162,263.  Multiple neurotrophic factors and their receptors have been 
implicated in human PDAC; increased GDNF, GFRα1, NGF, TRKA, ARTN, and GFRα3 have 
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been described in human PDAC tissue155–161.  In particular, increased NGF and ARTN is 
significantly correlated with nerve hypertrophy in human PDAC155,156.  In vitro, isolated 
myenteric plexuses exposed to extracts from human PDAC tissue exhibit increased neurite 
density compared to normal medium and this effect can be blocked by depletion of NGF or 
ARTN from the tumor extract156,168.  Increased NGF and TRKA in PDAC also correlates with 
patient report of pain119,157,159, suggesting that intrapancreatic neurotrophic factor expression in 
PDAC promotes peripheral nerve sprouting and sensitizes pancreatic sensory afferents.   
PDAC cell lines have been shown to express a variety of growth factor receptors 
including TRKA, TRKB, GFRα1, GFRα2, and GFRα3, suggesting that neurotrophic factors in the 
tumor microenvironment also influence tumor cells119. Increased NGF, TRKA, and GDNF in 
human PDAC tissue is significantly correlated with the degree of peripheral nerve 
invasion157,158,160 and in vitro, ARTN, GDNF, and NGF promote invasive behavior of human 
PDAC cell lines155,161,173–175.  Thus, neurotrophic factor expression in PDAC has a key role in the 
reciprocal relationship between the tumor and peripheral nervous system.   
In PDAC mice >16 weeks of age, changes in expression of neurotrophic factors and 
neurotrophic factor receptors are similar to those described in human PDAC, with significant 
increases in Ngf, Trka, Gdnf, and Gfrα2 and a significant decrease in Gfrα3.  Because Gfrα3 is 
expressed by vascular smooth muscle cells, its decrease may reflect the relatively avascular 
nature of the tumor. However, in contrast to human studies, Artn expression is not significantly 
increased when normalized to the least-changed housekeeping gene, Rpl13a.  Significant 
increases in expression of normalization genes were observed in PDAC mice with advanced 
tumors, suggesting that the pancreas/tumor of older PDAC is quite different from that of age-
matched control mice. This result is consistent with extinction of background pancreas observed 
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in some PDAC mice with advanced disease. An alternative normalization procedure, based on 
the amount of cDNA amplified, was also employed to obtain a more complete picture of 
neurotrophic factor levels in the tumor.  In this comparison, we find that Ngf, Trka, Gdnf, Artn, 
Bdnf, Nrtn, and their receptors, except Gfrα3, were significantly increased in the tumors of 
PDAC mice when compared to control pancreas. Therefore, neurotrophic factor signaling in 
PDAC likely plays a prominent role in shaping tumor innervation and the tumor 
microenvironment in both human and murine PDAC.  
4.4.2 Changes in neurotrophic factor expression begin in pre-malignant stages of tumor 
development in PDAC mice 
In tPDAC mice, the presence of hyperinnervation in regions of the pancreas at 6-8 and 10-12 
weeks of ages suggests that a neurotrophic factor-rich, “pro-growth” microenvironment is 
present at pre-malignant stages of PDAC development.  While only Gfrα2 is significantly 
increased at 6-8 weeks, the regions of PanIN and associated fibrosis in the pancreas are relatively 
small at this time point; making detection of changes in neurotrophic factor expression within the 
whole pancreas difficult.  It is possible, however, that undetected local changes in growth factors 
in the microenvironment surrounding the developing PanIN lesions could affect nearby 
pancreatic afferents.  At 10-12 weeks, when more PanIN lesions, lobular pathology, and regions 
of hyperinnervation are present, Ngf, Trkb, Nrtn, and Gfrα2 mRNA levels are significantly 
increased in the pancreas of PDAC mice compared to controls.  Increased growth factor and 
growth factor receptor expression in the pancreas at these pre-malignant time points could be 
coming from tumor precursor cells in the PanIN lesions, infiltrating immune cells, or local 
stromal cells such as stellate cells.     
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Regardless of the source, changes in neurotrophic factor signaling in the pancreas that 
begin prior to the development of cancer are predicted to have both direct and indirect effects on 
tumor progression from PanIN to PDAC. Given that tumor cells express a variety of growth 
factor receptors, it is possible that tumor precursor cells could also express neurotrophic factor 
receptors and be directly affected by increased neurotrophic factors in the pancreas.  
Additionally, exposure to neurotrophic factors could induce nerve sprouting/hypertrophy in 
pancreatic afferents as well as sensitize them, resulting in increased activation and neurogenic 
inflammation.  Activated afferents have been shown to release a variety of pro-inflammatory 
molecules such as CGRP, SP, and ATP that could drive neurogenic inflammation localized to the 
regions of the pancreas containing PanIN, fibrosis, and hyperinnervation.  Thus, neurotrophic 
factors in the pancreas can indirectly drive disease progression through sensitization of 
pancreatic afferents.     
4.5 PERINEURAL TUMOR INVASION IN MOUSE PDAC 
4.5.1 Perineural invasion is a common and important component of PDAC 
Previous studies have shown that intrapancreatic PNI is present in up to 100% of PDAC cases 
(reviewed in118,128,129).  Intra- and extra-pancreatic perineural invasion correlate with worse 
disease prognosis, post-operative recurrence, and decreased survival time52–57,130–133.  Both 
PDAC-related pain and local tumor spread to retroperitoneal structures are thought to be related 
to perineural tumor invasion52,134–136 (reviewed in119).  Thus, PNI in PDAC represents an 
important component of the disease that, if blocked, could result in significant improvement in 
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morbidity and mortality.  Unfortunately, little is known about the mechanisms underlying the 
development of PNI in human PDAC and previous studies of PNI have relied upon in vitro co-
culture assays or xenograft models139,155–158,160–162,168,169,172,173,175–178,230–232,235,264,265. Therefore, 
we employed pancreas-specific lineage tracing using tPDAC mice to determine whether intra- or 
extra-pancreatic PNI occurs in murine PDAC. 
4.5.2 Perineural invasion occurs in PDAC mice 
Intrapancreatic PNI was difficult to definitively detect in tPDAC mice at any age, but PGP9.5+ 
fibers in regions of PanIN, fibrosis, or PDAC appeared to have an affinity for or tropism toward 
tdTomato+ cells.  Extra-pancreatic invasion of local and distant nerve ganglia was found in some 
cases.  The celiac ganglion of one tPDAC mouse was encased by a large tumor metastasis and 
tdTomato+ cells were present inside the ganglion.  This suggests that tumor cells migrated from 
the pancreas along sympathetic nerves that synapse in the celiac ganglion or the sensory afferents 
that run through it; similar to what may occur in locally advanced human PDAC.  In a different 
tPDAC mouse, tdTomato+ cells were discovered inside the T10 and T11 DRG and tumor 
encasement of the spinal cord was grossly visible from T9-T12, again suggesting tumor cell 
migration along sensory afferents leading to metastatic spread.  
In addition to providing a mode of extra-pancreatic tumor spread, PNI also involves 
damage to peripheral nerves that could trigger changes in gene expression in autonomic and 
sensory afferents.  In the case of the observed celiac ganglion PNI described above, many celiac 
ganglion neurons express ATF3, a marker for nerve injury.  Such injured neurons could have 
gene expression profiles similar to what is observed during peripheral nerve regeneration after 
injury including upregulation of growth factor receptors.  Invading tumor cells found in the 
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dorsal root and celiac ganglia also represent a potential source of growth factors, cytokines, and 
other factors that could alter neuron gene expression and excitability, leading to pain.  Therefore, 
PNI could contribute to the development of PDAC pain via physical damage of peripheral 
afferents as well as changes in nociception-related genes.        
How or why tumor cells invade and move along peripheral nerve fibers is not well 
understood and the use of lineage tracing to identify pancreatic cells invading peripheral ganglia 
could provide significant insight into this process, not only for PDAC, but also for other cancers 
in which PNI is prominent.  In vitro studies and xenograft models of PNI in PDAC suggest that 
perineural invasion and tumor migration along nerves requires a variety of secreted factors in the 
environment promoting mutual tropism as well as expression of particular genes in tumor cells 
such as adhesion molecules128,264.  One possibility is that nerves are drawn toward the tumor via 
neurotrophic factor signaling and subsequently activated.  Sensitized pancreatic afferents, in turn, 
secrete molecules such as glutamate, which are used by the tumor to promote growth or 
migration266.  Neurotrophic factors in the tumor microenvironment could also increase tumor cell 
migration or invasion by inducing gene expression changes via neurotrophic factor receptor 
activation and signaling.  Another possibility is that de-differentiated PDAC tumor cells assume 
a neuronal-like phenotype and the similarity between tumor cells and pancreatic afferents drive 
mutual tropism between the two85,128.  In vitro, transcription profiling in high-invasion and low-
invasion human pancreatic cancer cells lines suggests that there may be a particular genetic 
profile associated with PNI that could reveal targets for blocking or attenuating the process264.  
Therefore, future studies in which tumor cells that participate in PNI in vivo are isolated and 
transcriptionally profiled may critical insight necessary for understanding the mechanisms 
underlying tumor nerve interactions in PDAC and other cancers.     
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4.6 NEUROPLASTIC CHANGES IN THE PANCREAS OF PDAC MICE ALTER 
DRG PHENOTYPE 
4.6.1 Sensitization of DRG neurons in PDAC  
Neuroplastic changes frequently described in PDAC are similar to changes observed in 
inflammatory pancreatitis.  Pancreatitis is associated with increased growth factor expression167, 
hypertrophied nerve bundles136,167 and sensitized pancreatic afferents, all of which are thought to 
increase pancreatitis-related pain136,185. In rodent models of pancreatitis, pancreatic sensory 
afferents upregulate non-specific cation channels, such as TRPV1 and TRPA1, and demonstrate 
hypersensitivity210,211,214.  Given that chronic inflammation is also a component of PDAC, we 
hypothesized that similar changes in pancreatic sensory afferents would occur in PDAC mice.    
In the DRG of PDAC mice >16 weeks of age, expression of Trpv1 and Trpa1 is 
significantly increased and at 10-12 weeks of age, there is a non-significant trend toward 
increased Trpa1 expression.  We would expect to see changes in the DRG similar to what has 
been described in pancreatitis at pre-cancer stages of PDAC progression, when there is often 
acute or chronic inflammation in the pancreas. However, the number of DRG neurons in the T9-
T12 ganglia that innervate the pancreas is relatively small and based on the limited distribution 
of hyperinneravation at early time points, only a subset of pancreatic afferents is likely affected 
early.  Therefore, when analyzing whole DRG gene expression, it could be difficult to detect 
early changes in a relatively small number of neurons.   
Changes in TRP agonist evoked calcium transients in pancreas-specific DRG neurons, 
backlabeled with DiI, were examined using Ca2+ imaging.  Despite the increase in Trpv1 and 
Trpa1 expression in DRG T9-T12 of PDAC mice, there were no significant differences between 
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PDAC mice and controls in the number of DiI+ cells responding to application of the of either 
the TRPV1 agonist capsaicin, or the TRPA1 agonist mustard oil.  Increased expression of Trpv1 
and Trpa1 in whole DRG could be due to either an increased number of cells expressing the ion 
channels, or due to higher levels of expression in cells already expressing the ion channels.  The 
Ca+ imaging results would suggest the latter.  Pancreatic afferent neurons in PDAC mice did 
demonstrate significantly higher peaks in evoked calcium transients in response to administration 
of a 50mM KCl solution.  Therefore, exposure to neurotrophic factors in the pancreas could 
drive both changes in TRP channel expression as well as changes in DRG neuron activation.   
4.6.2 Neurogenic inflammation and PDAC disease progression  
The observed changes in pancreatic afferent phenotype could underlie both the development of 
PDAC-related pain as well as drive neurogenic inflammation as has been previously described in 
rodent models of pancreatitis.  Activation of TRPV1 in pancreatic afferents has been shown to 
drive neurogenic inflammation in the pancreas through release of peptides such as CGRP and 
SP, and importantly, blocking this process attenuates pain and inflammation210,211,214,216,218 
(reviewed in137,191,207).  Cgrp expression is significantly increased in the DRG of PDAC mice > 
16 weeks of age and there is a non-significant trend toward increased SP expression, suggesting 
that a similar process of peripheral afferent activation and neurogenic inflammation occurs in 
PDAC.  The process of afferent sensitization and the development of neurogenic inflammation 
may begin at pre-malignant stages of disease progression as increased expression of Cgrp was in 
the DRG from PDAC mice at 10-12 weeks of age.      
Chronic pancreatitis is associated with significantly increased the risk of pancreatic 
malignancy13–17,37 and pancreatic inflammation has been shown to promote disease progression 
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and metastases in mouse models of PDAC107–111,117.  Even a small population of sensitized 
pancreatic afferents localized to areas of PanIN and fibrosis at pre-tumor stages could drive 
neurogenic inflammation similar to what has been described in animal models of pancreatitis, 
and thereby contribute to or accelerate the progression from PanIN to PDAC.   
4.7 SUMMARY 
Early detection of PDAC is uncommon and little is known about how the nervous system might 
impact the transition from healthy pancreas to a pre-malignant PanIN stage to PDAC.  Here we 
demonstrate that neuroplastic changes associated with human PDAC are also observed in a 
transgenic mouse model of PDAC.  The similarities between the murine model of PDAC used in 
these studies and human PDAC are summarized in Table 12.  Importantly, I have found that 
these changes begin at a pre-cancerous stage of disease, implying an active role of the nervous 
system in disease progression. Furthermore, we demonstrated changes in sensory afferents 
including higher peak evoked calcium transients and increased expression of TRP channels as 
well as peptides associated with the generation of neurogenic inflammation.  
In conclusion, early neuroplastic changes in the pancreas are important not only for the 
subsequent development of PDAC-related pain, but also for driving disease progression from 
pre-malignant stages to cancer via sensory afferent sensitization and neurogenic inflammation 
(Figure 25).  Given that prominent PNI and tumor-nerve interactions have been described in a 
number of malignancies, interventions targeting the peripheral nervous system represent a novel 
tumor treatment strategy for variety of cancers, including PDAC. 
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Table 12.  Comparison of murine and human PDAC 
 PDAC Mice Human PDAC Is Murine Model Useful? 
Histological 
Progression 
-PanIN to PDAC 
-Multiple tumor loci 
-PanIN to PDAC 
-Single tumor locus 
Progression from pre-cancer lesions to 
malignancy in murine model closely parallels 
human disease. However the multiple tumor 
loci in the pancreas of PDAC mice could result 
in earlier detection of disease-related symptoms 
(e.g., pain) and pathology (e.g., inflammation). 
Tumor 
Sequelae 
-Jaundice 
-Bloody abdominal 
ascites 
-Enlarged gall bladder 
and/or common bile 
duct 
-Jaundice 
-Anorexia 
-Weight loss 
-Cachexia 
-Abdominal ascites 
-Courvoisier’s sign 
-Gastric outlet 
obstruction/ delayed 
gastric emptying 
-Nausea/vomiting 
-Diarrhea 
Some signs associated with human PDAC, 
such as jaundice and abdominal ascites, are 
observed in PDAC mice.  However, many of 
the symptoms such as anorexia and 
nausea/vomiting cannot be assessed.  
Additionally, weight loss and cachexia were 
not observed in PDAC mice, suggesting this 
murine model is not useful for studying these 
PDAC sequelae. 
Common 
Metastases 
-Liver 
-Peritoneum 
-Lung 
-Liver 
-Peritoneum 
-Lung 
A similar pattern of metastases is observed in 
PDAC mice and human PDAC, suggesting 
PDAC mice are a useful for studying disease 
dissemination. 
Neuroplastic 
Changes 
-Hyperinnervation 
beginning at PanIN-
only stage 
-Increased neural 
density 
-Neuritis 
Similar neuroplastic changes are observed in 
murine and human PDAC suggesting that 
PDAC mice are a useful model for studying 
changes in pancreatic innervation throughout 
PDAC development and progression. 
Neurotrophic 
Factors 
(and 
receptors) 
-Increased 
neurotrophic factor 
expression beginning 
at PanIN-only stage 
-Expression of 
neurotrophic factors in 
murine PDAC cell 
lines 
-Increased 
neurotrophic factor 
expression in PDAC 
tissue 
-Expression of 
neurotrophic factors 
in human PDAC cell 
lines 
Similar profiles of neurotrophic factor 
expression are observed in the pancreas of 
PDAC mice and human PDAC tissue.  Both 
murine and human PDAC cell lines express a 
variety of neurotrophic factors and receptors.  
This suggests neurotrophic factors play an 
important role in the tumor microenvironment 
and PDAC mice are a useful model for 
studying that role.   
PNI 
-Present in extra-
pancreatic ganglia 
-Present in intra-
pancreatic nerves 
-Present in extra-
pancreatic nerve 
plexuses 
Although intra-pancreatic PNI was not 
definitively observed in PDAC mice, the 
presence of extra-pancreatic PNI suggests 
similar modes of tumor spread along nerves in 
PDAC mice and human PDAC.  Thus, PDAC 
mice are a useful model for studying tumor-
nerve interactions including PNI.   
Pain 
-Hunching observed at 
PanIN-only stages 
could represent early, 
pain associated with 
pre-malignant lesions 
-Pain-related behavior 
is observed after the 
development of PDAC 
-Pain is a common 
symptoms at 
presentation and 
becomes more 
prevalent/severe 
with disease 
progression 
Pain-related postural changes may be present at 
pre-cancer stages in PDAC mice but not in 
human PDAC.  However, the development of 
pain-related behavior changes after PDAC is 
present in PDAC mice suggests that this 
murine model will be useful for studying 
tumor-nerve interactions that underlie the 
development of PDAC pain.   
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Figure 25.  Afferent sensitization, pain, and neurogenic inflammation in PDAC 
Genetic and environmental factors contribute to the development of PanIN lesions, fibrosis, and 
inflammation that can result in PDAC.  During PDAC development, increased production of 
neurotrophic factors and cytokines in the pancreas sensitize pancreatic afferents, leading to 
changes in pancreatic innervation and altered gene expression in dorsal root ganglia (DRG) 
neurons.  Increased expression of nociception-related genes such as TRPV1 and TRPA1 increase 
the excitability of pancreatic afferent neurons causing pain.  These changes contribute to 
increased release of CGRP and SP, neuropeptides that underlie neurogenic inflammation in the 
pancreas, driving disease progression from precancerous PanIN lesions to PDAC.   
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4.8 FUTURE DIRECTIONS 
In future studies I will directly test the hypothesis that blocking neurotrophic factor signaling in 
the pancreas of PDAC mice will prevent or attenuate changes in pancreatic afferent phenotype 
and PDAC-related pain by inhibiting neurotrophic factor signaling by injection of antibodies that 
bind neurotrophic factors such as NGF214,226,232–234,241 or by treatment with a small molecule 
TRK inhibitor231. We predict that blocking neurotrophic factor signaling in the pancreas will 
prevent changes in gene expression in pancreatic afferents, and attenuate PDAC-related pain. 
Blocking afferent sensitization should also prevent neurogenic inflammation in the pancreas and 
delay the development and/or progression of tumor growth in PDAC mice.  We will further 
examine the role of neurogenic inflammation in the development and progress of PDAC using 
two additional strategies targeting pancreatic afferents: treatment with TRP channel antagonists 
that have been shown to be effective in attenuating inflammation and pain associated with acute 
and chronic pancreatitis210,211 and denervation of sensory afferents via neonatal capsaicin 
treatment216,221,267,268.  
It is possible that use of these strategies may block afferent sensitization, PDAC-related 
pain, and neurogenic inflammation, but not influence tumor development or progression in 
PDAC mice.  This would suggest that peripheral nervous system participation is not required for 
disease progression, however it would not rule out its contribution to the disease.  Furthermore, 
prevention of PDAC-related pain in PDAC mice using either of the first two strategies could lead 
to new strategies for treating cancer pain in patients with PDAC that may significantly improve 
quality of life.       
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